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Ras is the most frequently activated oncogene in human cancer. It is not only the 
most frequently mutated oncogene, but is also rendered hyperactive in the wild-
type form by aberrant regulation. Ras drives transformation and contributes to 
tumor aggressiveness by activating multiple downstream mitogenic effectors. Ras 
also possesses the paradoxical ability to induce apoptosis and senescence. Ras-
induced apoptosis is not well understood, but has been largely attributed to the 
RASSF tumor suppressors, particularly RASSF1A. RASSF1A mediates Ras-
induced apoptosis by activating pro-apoptotic proteins such as the MST kinases 
and BAX. RASSF1A is among the most frequently inactivated tumor suppressors 
in human cancer. Loss of RASSF1A expression by promoter hypermethylation 
uncouples Ras from its pro-apoptotic effectors, thus promoting unrestrained Ras 
mitogenic signaling. More recently, it has been suggested that RASSF1A may be 
not only an apoptotic effector for Ras, but also a general inhibitor of Ras activity. 
Several groups have reported modulation of Ras mitogenic signaling in response 
to RASSF1A suppression. However, the mechanism by which this occurs has not 
yet been elucidated. This dissertation establishes a novel, endogenous interaction 
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between RASSF1A and an important negative regulator of Ras, the RasGAP 
DAB2IP. We show that RASSF1A expression is an important determinant of 
DAB2IP protein levels. Loss of RASSF1A dramatically downregulates DAB2IP. 
This results in increases in Ras-GTP levels, Ras mitogenic pathway activation, and 
cell proliferation in both wild-type and mutant Ras lung cancer cells. This is the first 
example of a Ras effector regulating a Ras inhibitor, and the first example of a Ras 
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 Cancer is the second leading cause of death in the United States, with more 
than 1.8 million new cases and over 600,000 new deaths expected in 2020 [1]. 
The past three decades have seen a dramatic reduction in both the incidence and 
mortality of cancer. This is owed in large part to public health campaigns and 
advancements in screening and treatment. Indeed, the lung cancer death rate in 
the United States underwent its most precipitous decline on record in the past five 
years. Unfortunately, this shining accomplishment is somewhat dulled when put 
into context, in that the mortality rate of lung cancer had reached the greatest 
height from which to fall relative to other cancers. Still today, nearly one quarter of 
all cancer-related deaths are due to lung cancer—more than the next four deadliest 
cancers (prostate, breast, colorectal, and brain) combined [1]. 
 The three Ras genes—HRAS, KRAS, and NRAS—are probably the best 
characterized oncogenes in the human genome. Together referred to as simply 
Ras, they comprise the most frequently activated oncogenes in human cancer, 
with activating point mutations occurring in roughly one third of tumors across all 
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tissue types [2]. The frequency of Ras mutations underscores its importance in 
carcinogenesis. Mutational activation of Ras results in constitutive activation of 
multiple mitogenic pathways that regulate survival, transformation, and growth [3]. 
These pathways synergize to mediate transformation [4]. 
Early experiments involving Ras mutants demonstrated that Ras alone 
could only transform immortalized cells, and primary cells first required 
immortalization by cooperating mutations in genes such as p53 [5, 6]. Without 
immortalization, oncogenic Ras would induce apoptosis and premature 
senescence [7, 8]. It has since been determined that this paradoxical growth-
inhibitory ability of Ras is indeed physiological, and has largely been attributed to 
the RalGDS/AF-6 Ras association domain family (RASSF) of tumor suppressors 
[9]. RASSF1A is the best characterized member of the RASSF proteins and is an 
important mediator of Ras-induced apoptosis and cell cycle restriction [10-12]. 
 Interestingly, induction of apoptosis may not be the only mechanism by 
which RASSF1A mediates tumor suppression. It has been shown that in addition 
to induction of apoptosis, RASSF1A can modulate Ras mitogenic effector 
signaling, suggesting that RASSF1A may directly regulate Ras activation [13-17]. 
This work focuses on the mechanism by which RASSF1A modulates Ras 
mitogenic signaling. 
 While searching for novel binding partners for the RASSF1A tumor 
suppressor, we identified a direct interaction with another tumor suppressor, 
disabled homologue 2 interacting protein (DAB2IP), which is an important negative 
regulator of Ras [18]. Suspecting that this interaction was the basis for the 
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observed downregulation of Ras mitogenic signaling by RASSF1A, we confirmed 
this interaction and began to investigate its biological significance. Indeed, we 
discovered a novel role for RASSF1A. In this work, we present evidence that 
RASSF1A is a potent positive regulator of DAB2IP. We show that suppression of 
RASSF1A results in a concomitant and drastic reduction in DAB2IP protein levels 
in human lung cancer cells. This RASSF1A-mediated suppression of DAB2IP 
results in a corresponding upregulation of Ras-GTP and Ras mitogenic signaling 
in both mutant and wild-type Ras lung cancer cells. Furthermore, we show that 
simultaneous downregulation of RASSF1A and DAB2IP, both frequent events in 
cancer, enhances Ras signaling and growth in wild-type Ras cancer cells. Thus, 
we describe the first ever mechanism of Ras regulation by a downstream effector. 
 
1.2. Discovery of Ras 
 
In the 1960s, two murine retroviruses were discovered that possessed the 
ability to transform infected cells in rodent newborns [19, 20]. Some two decades 
later, it was revealed that the causative genes in these viruses were in fact rat 
genes that had been transduced into retroviral genomes [21, 22]. They were called 
Ha-ras and Ki-ras, after the Harvey and Kirsten rat sarcoma viruses in which they 
were discovered. Around the same time, the presence of oncogenes in the human 
genome was discovered, and in 1982 three independent groups realized that the 
human oncogenes being feverishly investigated were homologues of the rat ras 
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genes discovered 10 years prior [23, 24]. That same year, a third Ras gene was 
discovered in a neuroblastoma cell line; it was called NRAS [25, 26]. 
Now, 38 years after their discovery, these once marginally relevant rat 
genes are known to be the most frequently mutated oncogenes in human cancer 
[27]. As such, the Ras oncogenes have been the subjects of intense scrutiny in the 
field of cancer research. Early on, it was revealed that Ras was regulated much 
the same as other small G proteins, and the mutations found in cancer served to 
disrupt the normal GTPase cycle [23, 24]. 
 
1.2.1. Regulation of Ras 
 
Given the potent ability of Ras to induce transformation, it comes as no 
surprise that the Ras GTPase cycle is tightly regulated. Indeed, the transition 
between on and off states is controlled in both directions by two families of 
regulatory proteins. Guanine nucleotide exchange factors (GEFs) serve as positive 
regulators, catalyzing exchange of GDP for GTP. GTPase activating proteins 
(GAPs) negatively regulate Ras by potently stimulating its intrinsic GTPase activity 


















Figure 1: Model for Ras regulation. Ras is primarily localized to the inner leaflet 
of the plasma membrane. Ras is activated by mitogenic stimuli, such as binding of 
growth factors to their respective receptors. Receptor activation recruits, through 
adapter proteins, guanine nucleotide exchange factors (GEFs) to the plasma 
membrane, which bind inactive Ras and facilitate GDP release, allowing GTP to 
bind and activate Ras.  Ras then recruits and activates mitogenic effectors such 
as Raf. Ras signaling is silenced by stimulation of its intrinsic GTPase activity by 
GTPase activating proteins (GAPs).  
Reprinted with permission from Springer 
Nature: [Nat Rev Cancer] (Downward, 
Targeting RAS signaling pathways in cancer. 
Nat Rev Cancer, 2003. 3(1): p. 11-22.) 
Copyright 1969 
 
Reproduction Lic. #4827190088816 
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1.2.1.1. GTPase Activating Proteins 
 
In the mid-1980s, multiple reports demonstrated that Ras mutants 
commonly found in patient tumors exhibited diminished GTPase activity compared 
to its wild-type form. However, in vitro and in vivo data did not appear to correlate. 
The ability of Ras mutants to induce transformation in vivo was striking, but in vitro 
GTPase assays revealed only a modest impedance of GTPase activity in mutants 
[29]. This discrepancy was resolved in 1987, when it was discovered that a 
cytoplasmic protein called GTPase Activating Protein (GAP, now called p120GAP 
or RASA1) was responsible for the dramatic increases in GTPase activity of wild-
type Ras observed in vivo [30-32]. Three years later, a second RasGAP was 
discovered and called neurofibromin. This is the protein product of the causative 
gene in the eponymous heritable tumor syndrome neurofibromatosis type 1 (NF1) 
[33, 34]. NF1 was identified because of the high degree of homology between its 
catalytic GAP-Related Domain (GRD) and the GAP domain of p120GAP. 
A total of 14 RasGAPs have bene described in the literature today [35]. 
RasGAP proteins are a profoundly heterogeneous group apart from their GAP 
domains, sharing little to no sequence homology outside of that region and 
possessing different functional domains that confer unique biological properties 
[36, 37]. Critical to GAP activity is a highly conserved arginine residue, called an 
arginine finger. Upon Ras-RasGAP binding, the arginine finger is inserted into the 
active site wherein it serves two functions. First, the positive charge of the side 
chain neutralizes charges at the active site in the transition state of GTP hydrolysis. 
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Second, the arginine residue forms a hydrogen bond with the catalytic glutamine 
residue in the switch II region of Ras (Gln61), which positions it appropriately in 
the active site to catalyze GTP hydrolysis [38]. 
 
1.2.1.2 Guanine nucleotide Exchange Factors 
 
Just as GTP hydrolysis by Ras requires stimulation from regulatory 
RasGAPs, GDP-GTP exchange is also a tightly regulated process. The first 
RasGEF, CDC25, was identified in 1987 in yeast; however, its ability to catalyze 
nucleotide exchange in Ras was not discovered until 1991 [39-41]. That same 
year, the RasGEF Son of Sevenless (SOS) was identified as a downstream 
effector of EGF in Drosophila; its homology to yeast CDC25 was reported the 
following year [42, 43]. These studies led to the discovery of mammalian RasGEFs 
in 1992 [24].  
 GEFs do not actively exchange GTP for GDP, rather they bind to Ras-GDP 
and facilitate GDP dissociation. GTP is present at higher concentrations than GDP 
in the cell, and therefore predominantly fills the empty nucleotide binding site on 
Ras [44]. GEF structure is conserved within subfamilies, therefore the mechanisms 
by which GEFs facilitate GDP dissociation are dependent on the GEF subfamily 
and the GTPase being activated [28, 45]. They do, however, share a general 
mechanism of remodeling the switch regions of Ras to lower phosphate binding 
affinity [28]. RasGEFs are members of the CDC25 family. CDC25 family GEFs 
contain a highly conserved CDC25 domain and, usually, an N-terminal Ras 
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Exchanger Motif (REM). The mechanism by which these family members catalyze 
GDP dissociation is two-fold. First, the GEF inserts a projection (an alpha-helix in 
the case of the RasGEF SOS1) into the active site of Ras, which distorts switch I 
away from the active site. Second, it induces a conformational change in switch II, 
which results in a Mg2+ ion that is critical for stabilizing the nucleotide being 
occluded from the active site by switch II residues [46]. As a result, the alpha and 
beta phosphate are destabilized in the active site, and GDP is ultimately released. 
The GEF is then displaced by the binding of a new nucleotide [28]. 
 
1.2.2.  Structure and function  
 
Early investigations into the nature of these transforming genes revealed 
that their oncogenic properties were conferred by an alarmingly simple 
mechanism: a single missense mutation [47-50]. The ability of Ras proteins to bind 
GDP and GTP was appreciated early on [24]. It was suspected that Ras may 
function like the small G proteins known to transduce hormone signals into the cell 
[51]. The apparent wide tissue distribution and high frequency of mutation of Ras 
in human tumors underscored the need to understand its role in the molecular 
basis of cancer [24, 52]. 
 




In humans, there are three Ras genes—HRAS, KRAS, and NRAS—that 
encode four 188-189 amino acid proteins (KRAS produces two splice variants, K-
Ras4A and K-Ras4B) [53]. The Ras proteins share 80-90% primary sequence 
homology as well as a high degree of structural homology, particularly in the N-
terminal half of the sequence (figure 2) [54]. This region, residues 1-86, has been 
termed the effector lobe and has 100% sequence identity among the Ras proteins. 
Residues 87-166 constitute the allosteric lobe, which has a sequence identity of 
90%. Together, these lobes represent the catalytic G-domain of Ras, which is 
responsible for GTP binding and hydrolysis as well as effector binding. At the 
extreme C-terminus lies the hypervariable region (HVR) that contains post-
translational modification sites. As the name implies, the HVR exhibits very little 
sequence identity [55].  
 
1.2.2.2. 3-dimensional structure and mechanistic function 
 
In 3 dimensions, the G-domain of Ras consists of six beta-sheets and five 
alpha-helices, forming a hydrophobic core connected by 10 loops (figure 3) [56]. 
Five of these loops exist on one facet of the G-domain and collectively mediate 
nucleotide and effector binding; loops 1-3 are in the effector lobe while loops 4 and 
5 are in the allosteric lobe. Loop 1 (also called the P-loop or Walker A motif) and 












Figure 2: Overview of Ras isoforms. In humans, there are three Ras genes—
KRAS, HRAS, and NRAS, that code for four Ras proteins (KRAS is alternatively 
spliced at exon 4 to give rise to K-Ras4A and K-Ras4B, of which K-Ras4B is the 
major isoform). The effector lobe (residues 1-86 are identical in all 4 protein, and 
overall the G domains share ~95% sequence homology. At the extreme C-
terminus lies the hypervariable region. This region exhibits almost no homology 
among the Ras isoforms, save for the ending CAAX motif. These last four residues 
are required for post-translational farnesylation, a modification that is critical to 
proper function and subcellular localization.  
Reprinted with permission from Springer 
Nature: [Nat Rev Cancer] (Schubbert et al., 
Hyperactive Ras in developmental disorders. 
Nat Rev Cancer, 2007. 7(4): p. 295-308.) 
Copyright 1969 
 














Figure 3: 3-dimensional structure of Ras. Ras proteins contain a hydrophobic 
core made of six beta-sheets and five alpha-helices, connected by 10 loops. Five 
of these loops are on the cytoplasmic-facing facet of the protein and constitute the 
nucleotide and effector binding domains.  The model shows Ras in complex with 
the catalytic arginine figure of a GTPase activating protein (GAP, purple loop), 
which coordinates critical residues on Ras—G12, G13, and Q61 (yellow 
spheres)—to facilitate GTP hydrolysis.  
Reprinted with permission from Springer 
Nature: [Nat Rev Cancer] (Schubbert et al., 
Hyperactive Ras in developmental disorders. 
Nat Rev Cancer, 2007. 7(4): p. 295-308.) 
Copyright 1969 
 
Reproduction Lic. #4827301455060 
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proteins) are responsible for beta/gamma phosphate stabilization and guanine 
nucleotide specificity, respectively [44, 55]. Loop 5 also contributes to nucleotide 
binding, mostly indirectly through stabilization of loop 4 [55, 57]. Loops 2 and 3 are 
major components of two highly mobile regions of Ras, the switch I and switch II 
regions, respectively. 
Switch I and II regions undergo conformational changes in response to GTP 
binding and hydrolysis due to interactions with the gamma phosphate. The 
conformational change in these regions is responsible for the “switch” between on 
and off states of Ras [44, 58]. In the on, GTP-bound state, the switch regions form 
a platform to which effectors may bind. Different effectors interact with Ras in 
different (and sometimes multiple) ways, but there is a strong preference for 
binding to the switch I region [59]. The switch II region contains the catalytic 
glutamine residue (Gln61) that is responsible for GTP hydrolysis [60]. 
 
1.2.2.3. Post-translational modification 
 
 It was understood very early that Ras was not a cytosolic protein, but rather 
was localized to the membrane [61, 62]. The first investigations into what 
modifications of Ras may confer membrane localization revealed three important 
characteristics: 1) that H-Ras could be palmitoylated, 2) that the C-terminus—
specifically Cys186—was critical to membrane localization, and 3) that membrane 
localization was necessary for Ras to transform cells [63, 64]. This led to the 
incorrect assumption that H-Ras must be palmitoylated on Cys186 [24]. It would 
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be several years before it was discovered that the critical Cys186 residue was part 
of a motif known in yeast to result in protein prenylation. 
 The C-terminus contains almost all the sequence and structural variability 
of the Ras proteins, particularly the last 22-23 residues that make up the HVR 
(figure 2). However, Cys186 is part of a highly conserved CAAX consensus 
sequence, first identified in yeast, that is a signal for three post-translational 
modifications [65]. The CAAX motif—wherein C is cysteine, A is an aliphatic 
residue, and X is any amino acid—is farnesylated (at Cys186), cleaved, and 
methylated in all Ras isoforms [66-69]. After farnesylation, the variability present 
in the HVR dictates which of two divergent paths Ras takes to the plasma 
membrane. Present in the HVRs of H-Ras, N-Ras, and K-Ras4A are one or two 
additional cysteine residues that are palmitoylated, resulting in their trafficking 
through the exocytic pathway to the plasma membrane [70, 71]. The HVR of K-
Ras4B lacks additional cysteine residues, but rather contains a poly-lysine 
sequence that interacts with negatively charged membranes (figure 4). K-Ras4B 
concentrates at the inner leaflet of the plasma membrane through a complex 
mechanism. First, upon synthesis, K-Ras4B binds to cytosolic transport protein 
such as PDE-δ, which shield the poly-lysine HVR from binding to endomembranes 
[72]. K-Ras4B is unloaded from PDE-delta onto perinuclear membranes, and is 
ultimately shuttled to the plasma membrane by the recycling endosome [72, 73]. 
Interestingly, K-Ras4A utilizes both a palmitoylated cysteine and a poly-lysine 

















Figure 4. Targeting of Ras to plasma membrane by post-translational 
modification. All Ras proteins possess a C-terminal CAAX motif, a signal for 
cysteine farnesylation. H-Ras, N-Ras, and K-Ras4A contain additional cysteine 
residues in the hypervariable region (HVR) that are palmitoylated by the Golgi and 
target Ras to the plasma membrane via the exocytic pathway. K-Ras-4B (as well 
as K-Ras 4A) contain a polybasic sequence in the HVR that targets Ras to the 
membrane via the recycling endosome system, utilizing chaperone protein such 
as PDE6-δ.  
Reprinted with permission from American 
Association for Cancer Research: [Clin Cancer Res.] 
(Cox et al., Targeting RAS Membrane Association: 
Back to the Future for Anti-RAS Drug Discovery? 
Clin Cancer Res, 2015. 15;21(8):1819-27.) 
Copyright 2015 
 
Reproduction Lic. #4827310117028 
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1.2.3. Signaling, mutation, and cancer 
 
 The Ras proteins were initially discovered because of their potent ability to 
transform cells. By the early 1990s, the basic biochemistry of Ras—the GTPase 
cycle, gross effects of mutation on GTP hydrolysis, and the physical state of the 
protein necessary for transformation—had been well established. Still unknown 
were the factors activated by Ras-GTP that confer its oncogenic nature. To identify 
Ras effector proteins, several groups performed yeast two-hybrid screens. In swift 
succession, the three canonical Ras effectors were identified. 
 
1.2.3.1. Canonical mitogenic Ras signaling 
 
 Classical activation of Ras signaling begins at the cell surface with the 
binding of a ligand, epidermal growth factor (EGF) or platelet-derived growth factor 
(PDGF) to their respective receptors EGFR and PDGFR [75]. Receptor activation 
leads to binding of growth factor receptor-bound protein 2 (GRB2) [76], which in 
turn recruits the RasGEF SOS1 to the plasma membrane where it can activate 
membrane-bound Ras [77-80]. Activated Ras-GTP is then able to bind and 
activate its effectors. The first Ras effector identified was the well-known viral 
oncoprotein Raf [81]. 
 The serine/threonine kinase Raf was identified as a downstream binding 
partner of Ras-GTP in Drosophila, C. elegans, and mammalian cells by multiple 
groups in 1993 [82-86]. Prior knowledge about the oncogenic properties of Raf 
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combined with more recent evidence of both Ras- and Raf- mediated activation of 
the mitogen-activated protein kinase (MAPK) cascade led to the rapid elucidation 
of the first Ras-regulated signaling pathway: Ras-Raf-MEK-ERK [23, 24, 87]. Raf 
is recruited to and activated at the plasma membrane by Ras-GTP [88]. There are 
three Raf isoforms: c-Raf/Raf-1, A-Raf, and B-Raf. All three are capable of 
phosphorylating the first component of the MAPK cascade, MAPK/extracellular 
signal-regulated kinase (ERK) kinase 1/2 (MEK1/2) [89]. MEK1/2 then activate 
ERK1/2, which regulate transcriptional activity by phosphorylating transcription 
factors [87], some of which have been implicated in Ras-mediated transformation 
[90]. 
 In 1991, it was reported that phosphatidylinositol 3-kinase (PI3K) activity 
increased in response to Ha-ras mediated transformation in epithelial cells [91]. In 
1994, the direct, GTP-dependent interaction between Ras and the catalytic p110 
subunit of PI3K was reported, thus establishing the second canonical Ras effector 
[92]. As its name suggests, PI3K catalyzes the phosphorylation of 
phosphatidylinositol 4,5-bisphosphate (PIP2) to form phosphatidylinositol 3,4,5-
triphosphate (PIP3), which activates the Ser/Thr kinase AKT (also known as protein 
kinase B (PKB)) [93]. AKT has multiple substrates that confer to it control of cell 
growth, proliferation, and survival [94, 95]. Specifically, AKT activates the pro-
survival/anti-apoptotic transcription factor NFκB, inhibits the pro-apoptotic BAD 
and Bax proteins, and antagonizes p53-induced apoptosis in order to favor cell 
survival [96]. PI3K-AKT promotes growth and favors transformation by activating 
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mammalian target of rapamycin (mTOR) signaling [97], a pathway that is 
dysregulated in most cancers [98]. PI3K-AKT also regulates the cell cycle [95].  
 The third canonical Ras effector identified is an activator of two other small 
GTPases that are structurally related to Ras. The Ras-like (Ral) GTPases, RalA 
and RalB, were discovered in 1986 and have been implicated in cellular processes 
ranging from vesicular trafficking to tumor formation and metastasis [99]. As a 
small GTPase, the Ral GTPase cycle is regulated by GEFs and GAPs. In 1994, 
the RalGEF Ral guanine nucleotide dissociation stimulator (RalGDS) was 
identified in a yeast two-hybrid screen as a Ras effector protein [100-102]. RalGDS 
activates the Ral GTPases, but not structurally similar GTPases such as Ras, Rho, 
or Rab [99]. The Ras-RalGDS pathway was not given a great deal of attention 
initially, as it appeared to play only a minor role in Ras-mediated transformation 
[24]. The Ral GTPases has been shown to be involved in a broad spectrum of 
biological processes [99]. Indeed, Ral has since been shown to play critical roles 
in several human cancers, and has even been deemed necessary for tumor 
development in an H-Ras-driven mouse model of skin cancer [103, 104].  
 
1.2.3.2. Mutation in cancer 
 
 The importance of Ras mutations to carcinogenesis was apparent at the 
inception of the Ras field, as it was the transforming power of Ras mutants that 
initially garnered the attention of researchers and led to its characterization. 
Numerous reports of mutations in codon 12, normally a glycine, in cancer cell lines 
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were published in the early 1980s [47, 48, 50]. Two 1984 publications 
demonstrating the presence of mutant Ras in tumor cells, yet the absence thereof 
in normal cells from the same patient, definitively proved that the link between Ras 
point mutation and malignancy was a naturally-occurring phenomenon, not just an 
artifact of serial passaging in cell culture [105, 106]. 
 Ras is predominantly mutated at codon 12 in human cancers, followed by 
codon 13 [107]. Mutations at codon 61 are observed in certain cancers, such as 
melanoma [35]. In fact, 97-99% of Ras mutations in all three isoforms are found in 
these three codons [24]. The most common mutations render Ras oncogenic by 
inhibiting GTP hydrolysis; however, these effects are more attributable to the 
inhibition of GAP activity than the intrinsic GTPase activity of Ras [29]. Targeted 
mutation of codon 12 demonstrated that every amino acid except glycine—present 
in the wild-type protein—and proline rendered Ras oncogenic [108]. The initial 
report concluded that an alpha-helical secondary structure must be required for 
Ras GTPase activity. However, analysis of the crystal structure of Ras bound to 
the p120GAP catalytic domain revealed that introduction of the arginine finger into 
the active site of Ras creates steric constraints therein such that even alanine is 
incapable of fitting in that space [38]. Interestingly, Gly12 mutants are still able to 
bind to RasGAPs, suggesting that glycine is more important for transition state 
formation as opposed to ground state [109].  
The same can largely be said for codon 13 mutations. Gly13 is positioned 
further away from the RasGAP arginine residue [38]. It thus appears that mutations 
here are slightly more forgiving, in that alanine and valine mutants are able to form 
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the transition state whereas larger amino acids cannot [38, 110]. Gln61 is the 
catalytic residue of Ras that activates a water molecule for GTP hydrolysis. 
Therefore, mutations at this codon do technically disrupt the intrinsic GTPase 
activity of Ras. However, differences in Ras GTPase activity are only appreciable 
upon stimulation with GAPs [28, 29]. As with the other mutation hotspots, 
extremely few amino acid substitutions—in this case, proline and glutamate—are 
non-transforming at position 61 [111].  
 Analysis of the pan-tumor mutation spectrum of Ras reveals patterns in the 
frequency and types of mutations in the three Ras genes that are dependent on 
the tissue type. This suggests that Ras isoforms may vary in their predisposition 
for activation from cell type to cell type [35]. Across all tissues, KRAS is the most 
frequently activated Ras gene by far, with mutations occurring in 22% of samples 
in the COSMIC database, followed by NRAS at 7%, then HRAS at 3%. 
KRAS mutations are predominant in cancers of the pancreas, colon, and 
lung [112-114]. KRAS mutations affect codon 12 in 80% of cancer cases of all 
types. G12D and G12V are the most common substitutions, representing in 36% 
and 24% of all KRAS mutations, respectively. Interestingly, G12C mutations, which 
account for just under 15% of KRAS mutations overall, are overwhelmingly 
represented in lung cancer, where its frequency surpasses that of G12D and G12V 
mutations combined [35]. It was recently discovered that K-RASG12C retains the 
ability to complete the GTPase cycle [115, 116]. The implications of this are 
threefold: K-RASG12C 1) is susceptible to activation by upstream signals, 2) may be 
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rendered hyperactivated by upstream deregulation, and 3) may confer 
susceptibility to upstream targeted therapies such as tyrosine kinase inhibitors. 
Despite representing less than 10% of Ras mutations overall, NRAS is the 
predominant isoform mutated in melanoma and acute myelogenous leukemia 
(AML) [117, 118]. NRAS is mutated in 30% of melanomas, making it the second 
most common oncogenic driver in melanoma behind BRAF [119]. NRAS is 
mutated primarily at codon 61 [35]. HRAS is the least frequently mutated isoform, 
found in 3% of tumors. HRAS is associated with squamous cell cancers of the 
head and neck, and is mutated at codons 12 and 61 at roughly equal rates [35, 
54]. Whatever the specific substitution, mutational activation of Ras leads to 
sustained signaling through the canonical mitogenic effectors, which can synergize 
to mediate transformation. However, Ras can paradoxically stimulate apoptosis 
and senescence in response to mutational activation as a protective mechanism 
against transformation.  
 
1.3. RASSF family of tumor suppressors 
 
1997 reports demonstrating the ability of Ras to induce senescence and apoptosis 
naturally led to the hypothesis that additional effectors proteins for Ras must exist 
that regulate these effects (figure 5). In a span of three years, this hypothesis was 
confirmed with the discovery of NORE1A (also known as RASSF5) and RASSF1A, 















Figure 5. Ras regulates mitogenic and growth-inhibitory pathways. Ras, in 
both wild-type and oncogenic forms, possess the paradoxical ability to stimulate 
both growth-promoting and growth-inhibiting signaling pathways. Canonical Ras 
effectors—Raf, PI3K, and RalGDS—predominantly favor growth. Conversely, 
several Ras effectors, particularly RASSF proteins, induce apoptosis and 
senescence in response to Ras stimulation. Loss of RASSF expression uncouples 
Ras from growth inhibition, thus favoring transformation.   
Reprinted with permission from Springer 
Nature: [Oncogene] (Cox et al., Targeting RAS 
Membrane Association: Back to the Future for 
Anti-RAS Drug Discovery? Oncogene, 2003. 
22(56):8999-9006. Copyright 2003. 
 
















Figure 6. The classical RASSF proteins. The 10 RASSF proteins can be divided 
into two subfamilies, classical/C-RASSF and N-RASSF. Classical RASSF proteins 
have been extensively implicated in tumor suppression. They contain a conserved 
C-terminal Salvador-RASSF-Hippo (SARAH) domain and adjacent RalGDS/AF-6 
Ras association (RA) domain. RASSF1A and NORE1A/RASSF5, the major 
members of the family, also contain a C1/Diacylglycerol binding domain. Both 
RASSF1A and NORE1A are alternatively spliced to give rise to multiple isoform. 
RASSF1 has 8 isoforms, RASSF1A-H, of which RASSF1C is the major variant.  
Reprinted with permission from Springer 
Nature: [Cell Mol Life Sci.] (Iwasa et al., tumor 
suppressor C-RASSF proteins. Cell Mol Life 
Sci., 2018. 75(10):1773-1787. Copyright 2018. 
 
Reproduction Lic. #4827320549900 
 
 23 
NORE1A and RASSF1A were identified because of their RalGDS/AF-6 Ras 
Association (RA) domains. There are 10 RASSF proteins, which can be divided 
into two groups based on the location of the RA domain: C-terminal or N-terminal 
[123]. RASSF1-RASSF6 are in the C-terminal group and are considered the 
classical RASSF proteins (figure 6). They contain a conserved 
Salvador/Ras/Hippo (SARAH) domain adjacent to the RA domain that facilitates 
homo- and heterodimerization as well as connection to the Hippo kinases MST1 
and 2 [124]. The classical RASSF proteins are downregulated in human cancers, 
and most have been characterized as tumor suppressors [9, 123]. The N-terminal 
RASSF proteins, RASSF7-RASSF10, do not contain SARAH domains and their 
role in human disease is much less understood [125]. 
 
1.3.1. The RASSF1A tumor suppressor 
 
 RASSF1A is perhaps the best characterized member of the RASSF 
proteins. Numerous studies indicated that the 3p21.3 locus underwent loss of 
heterozygosity frequently and very early in lung cancer development, suggesting 
that a tumor suppressor gene was located there [126]. In 2000, the RASSF1 gene 
was discovered at that locus, and the resultant protein was shown to induce 
apoptosis in a Ras-dependent manner [121, 122]. RASSF1A has since been 




 The RASSF1 gene utilizes two promoters and eight exons that are 
alternatively spliced to give rise to eight isoforms, RASSF1A-H [127]. RASSF1A 
and RASSF1C are the predominant isoforms and are ubiquitously expressed. 
Their expression is driven by different promoters located in different CpG islands, 
and therefore may be differentially regulated by promoter methylation [130]. 
Indeed, hypermethylation of the RASSF1A promoter is a frequent and early event 
in many human cancers [127, 131]. Somatic mutations in RASSF1A have also 
been reported [132]; however, this is not considered a major mechanism of 
RASSF1A inactivation. Early studies in mice, wherein rassf1a-/- animals were more 
susceptible to spontaneous tumor formation than wild-type littermates, established 
the role of RASSF1A in cancer as a bona fide tumor suppressor [133].  
 
1.3.1.1. RASSF1A in RAS-mediated apoptosis 
 
  When the RASSF1 gene was first identified, it was immediately noted that 
it possessed the ability to suppress in vitro and in vivo growth of lung cancer cells 
and induce apoptosis in a GTP-dependent manner [121, 122]. It has since been 
demonstrated that RASSF1A utilizes several pathways to mediate this apoptotic 
effect. Perhaps the best characterized mechanism of RASSF1A-mediated 
apoptosis is activation of the Hippo pathway [134]. The Hippo pathway is a highly 
conserved kinase cascade, first identified in Drosophila as a regulator of tissue 
growth, that has since emerged as a critical mediator of malignancy and 
metastasis [135, 136]. 
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 The Hippo pathway begins at the MST kinases (MST 1/2). In response to 
Ras activation, RASSF1A binds MST1/2 and stabilizes their active state by 
preventing dephosphorylation by PP2A domain [137-140]. When activated, 
MST1/2 phosphorylate the kinases LATS1/2. LATS1/2 in turn phosphorylate their 
targets YAP and TAZ. This leads to cytoplasmic retention and subsequent 
degradation of YAP and TAZ, and a switch in YAP affinity from pro-proliferative 
TEAD and SMAD family transcription factors to pro-apoptotic p73 [138, 141, 142]. 
LATS1 also binds to and inhibits the ubiquitin ligase MDM2, a negative regulator 
of the p53 tumor suppressor, thereby stabilizing p53 and inducing apoptosis [137]. 
RASSF1A can also directly bind MDM2 after phosphorylation following DNA 
damage [143]. This leads to MDM2 auto-ubiquitination and degradation [144]. 
 RASSF1A can also induce mitochondrial apoptosis by activating BAX. In 
response to TNF or mutant K-RAS, RASSF1A binds to modulator of apoptosis 
(MOAP-1), opening the conformation of MOAP-1 to facilitate binding to the pro-
apoptotic protein BAX [11, 145]. The MOAP-1-BAX interaction induces 
conformational change of BAX, insertion into the mitochondrial membrane, and 
cytoplasmic release of cytochrome c [146]. 
 
1.3.1.2. Other tumor suppressive effects of RASSF1A 
 
 In the cell, RASSF1A does far more than serve as a kill switch for Ras 
mutants. Since its discovery, roles for RASSF1A have been found in cell motility, 
invasion, and metastasis [12, 147]; cell cycle progression [10]; DNA damage repair 
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[148]; organelle trafficking and cell-cell communication [149]; and inflammation [9, 
150]. Interestingly, much of RASSF1A activity, including its regulation of cell 
proliferation and apoptosis, is mediated through its interaction with and 
stabilization of microtubules [129]. 
 RASSF1A binds to microtubule associated proteins (MAPs), which mediate 
its interaction with microtubule filaments [151, 152]. This interaction prevents 
deacetylation of microtubules by histone deacetylase 6 (HDAC6), resulting in the 
accumulation of hyper-stable circular microtubule bundles [152, 153]. RASSF1A-
mediated stabilization of microtubules is also associated with mitotic arrest and 
inhibition of DNA synthesis [151, 152]. Mitotic arrest is mediated by regulation of 
centrosomes by RASSF1A. Centrosomes are critical regulators of mitotic spindle 
assembly [154]. Whereas knockdown of RASSF1A results in multipolar spindle 
formation, overexpression of RASSF1A inhibits centrosome separation, providing 
an explanation for why RASSF1A promotes G2/M arrest specifically [151, 155, 
156].  
 RASSF1A appears to regulate cell migration and cell cycle progression by 
multiple parallel mechanisms. Increases in invasion and metastasis observed 
upon RASSF1A depletion have also been attributed to disruption of cell-cell 
adhesions [12, 157]. RASSF1A negatively regulates Janus kinase (JNK) activity 
and subsequent cyclin D1 accumulation, thereby inhibiting G1-S transition in 
addition to G2-M [158]. 
 More recently, the ability of RASSF1A to regulate inflammation has been 
reported. Chronic inflammation is an important driver of tumor development and 
 
 27 
progression [159, 160]. RASSF1A-deficient animals and tumors exhibit elevated 
IL-6 production [14, 150]; tumors also exhibit increased macrophage invasion [14]. 
Part of the oncogenic program of YAP is upregulation of Il-6 production[161]. 
Moreover, Il-6 has been shown induce epithelial-to-mesenchymal-transition 
(EMT). Thus, control of inflammation and apoptosis by RASSF1A may be linked 
[129].  
 
1.3.2. A role for RASSF1A in RAS regulation 
 
 A final and curious aspect of RASSF1A activity is its ability to modulate 
mitogenic effectors of Ras. Modulation of the three canonical Ras mitogenic 
pathways—PI3K-AKT, Raf-MEK-ERK, and RalGEF-Ral—in response to 
RASSF1A depletion have been reported [13, 14]. Some of this may be explained 
by simple stoichiometry. Less RASSF1A-bound Ras will inevitably lead to more 
PI3K, RAF, and RalGDS-bound Ras. However, RASSF1A has been shown to 
directly modulate both AKT and RAF activity through the MST kinases [9, 162, 
163]. MST2 binds Raf and inhibits its activation by Ras [16]. RASSF1A competes 
with Raf for MST2 binding [138], and therefore titrates the degree of Raf inhibition 
by MST2. These interactions suggest that RASSF1A should serve to positively 
regulate Raf [9]. However, MST2 is also regulated by AKT, which phosphorylates 
MST2 and increases its affinity for RASSF1A [15]. This should theoretically result 
in simultaneous activation of RASSF1A-Hippo and Raf-MEK-ERK pathways, thus 
 
 28 
the ultimate outcome of these interactions is unclear. Others have shown that 
RASSF1A loss activates Raf [14, 17].  
 As AKT regulates MST2, RASSF1A1 regulates AKT activity, in part through 
MST1 [13, 162, 163]. MST1 directly binds AKT1 and both MST2 kinases suppress 
activating phosphorylation of AKT at T308 and S473 [163]. In addition to 
preventing dephosphorylation, RASSF1A also stabilizes MST1/2 protein levels 
through an unknown mechanism [140, 162]. RASSF1A suppression depletes 
MST1 protein and results in increased AKT phosphorylation at T308 [162]. 
 While the ability of RASSF1A to inhibit PI3K-AKT activity is established, 
reports describing the interactions between RASSF1A, Raf, and the MST kinases 
do not provide a concise mechanism of RASSF1A-mediated regulation of Raf. 
Moreover, they do not correlate with observed increases in Raf activity upon 
RASSF1A depletion. The recent report of RASSF1A negatively regulating Ral 
activation underscores the potential for a simpler, universal mechanism by which 
RASSF1A restrains Ras mitogenic signaling. The Clark group recently identified 
and confirmed a novel binding partner for RASSF1A that explains its control over 

















Figure 7. overview of DAB2IP signaling. DAB2IP is a RasGAP and bona fide 
tumor suppressor with multiple Ras-independent functions. DAB2IP can directly 
modulate Ras activation through its GAP domain. DAB2IP can bind to activated 
VEGFR2 and inhibit its induction of angiogenesis. Finally, DAB2IP is a critical 
mediator of TNF-induced apoptosis. Upon TNFR activation, DAB2IP is 
phosphorylated, which allow for simultaneous activation of pro-apoptotic ASK-
JNK signaling, direct inhibition of the pro-survival PI3K-AKT complex, and 
suppression of TRAF2-induced activation of NFκB, an important regulator of 
survival, inflammation, and transformation.  
Reprinted with permission from Company of 
Biologists: [J Cell Sci.] (Harrell Stewart and 
Clark, Pumping the brakes on RAS – negative 
regulators and death effectors of RAS. J Cell 
Sci, 2020. 133(3):jcs238865. Copyright 2020. 
 




1.4. DAB2IP: RasGAP, tumor suppressor, TNF transducer 
 
 Disabled homologue 2(DAB2) interacting protein (DAB2IP) is one of 
fourteen RasGAPs in the human genome and is among the best characterized 
[36]. While its GAP activity is required for full expression of its tumor suppressive 
power, additional functional domains of DAB2IP allow it modulate numerous 
biological processes involved in cancer, including angiogenesis, inflammation, 
proliferation, and apoptosis [164-167].  
 
1.4.1. Discovery of DAB2IP 
 
 Disabled homologue 2 (DAB2) interacting protein (DAB2IP) was first 
identified in a 2002 yeast two-hybrid screen as an N-terminal binding partner for 
the tumor suppressor DAB2, originally called differentially expressed in ovarian 
carcinoma-2 (DOC2) [18]. Its original characterization established several 
important aspects of the function of DAB2IP and its role in human cancer [18]. 
DAB2IP was found to possess several putative functional domains, including 
RasGAP homology (GAP), proline rich (PR), leucine zipper dimerization (LZ), and 
Src homology 3 (SH3). The RasGAP activity of DAB2IP was confirmed in vitro and 
in prostate cancer cells, with corresponding suppression of Raf-MEK-ERK 
signaling and 2D growth when overexpressed. It was found to be expressed in 
wide variety of normal tissues including prostate, as well as in primary prostate 
tumor cell lines, but was markedly downregulated in metastatic cell lines. This led 
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to the correct speculation that DAB2IP was involved in prostate cancer 
progression[18, 168]. 
 
1.4.2. DAB2IP in cancer – regulation and signaling 
 
 DAB2IP activity is frequently lost multiple cancers, including prostate, 
breast, and lung [169]. One report mentions mutational inactivation of DAB2IP in 
breast cancer; otherwise, mutation of DAB2IP appears to be a rare event [170]. 
Instead, tumors utilize a variety of mechanisms to subvert DAB2IP-mediated tumor 
suppression [171]. Aberrant histone deacetylation and promoter methylation has 
been reported in prostate cancer [168, 172]. Aberrant promoter methylation has 
also been reported in breast, lung, gastrointestinal, and brain cancers [173-176]. 
DAB2IP activity can also be suppressed by microRNA-mediated downregulation, 
ubiquitin-mediated degradation, inhibitory phosphorylation, and sequestration by 
mutant p53 [171, 177-179]. The multifaceted approach employed to abrogate 
DAB2IP activity in cancer implies both that loss of DAB2IP confers significant 
survival and/or proliferative advantage to tumor cells, and that DAB2IP must be a 
powerful tumor suppressor (figure 7). 
 
1.4.2.1. DAB2IP favors apoptosis over survival 
 
 A second group identified DAB2IP in a yeast two-hybrid screen as a binding 
partner of apoptosis signal-regulating kinase 1 (ASK1) and named it ASK1 
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interacting protein (AIP1) [180]. ASK1 is an upstream activator of c-Jun N-terminal 
kinase (JNK) and p38 MAPK which regulate survival and apoptosis [181]. In a 
series of reports, these two groups elucidated a mechanism in which DAB2IP 
serves as a critical determinant in the decision between survival and apoptosis in 
response to TNF-TNFR signaling [180, 182-184]. 
 In resting cells, DAB2IP is in a closed conformation in complex with TNFR 
[180, 182]. The PR domain of DAB2IP is responsible for maintaining this closed 
conformation [182]. Upon TNFR activation by TNF, TRADD is recruited to the 
receptor and serves as a platform for the formation of a large complex involving 
TRAF2, DAB2IP, ASK1, RIPK1, IKK, and MAP3K [184-187]. TRAF2 is an 
important transducer of TNFR signaling, capable of stimulating pro-apoptotic ASK-
JNK and pro-survival NFκB pathways [188]. This complex is released into the 
cytoplasm, where DAB2IP adopts an open conformation and is phosphorylated at 
S604 by either RIPK1 or ASK1, a required modification for activation of ASK1 
[184]. ASK1 is then dephosphorylated by PP2A and 14-3-3, the inhibitor of ASK1, 
is transferred to phosphorylated DAB2IP, allowing for ASK1-mediated activation 
of JNK and subsequent induction of apoptosis [180, 184, 189]. The interaction 
between DAB2IP and ASK1 is significantly enhanced by TRAF2 [180]. DAB2IP 
simultaneously inhibits TNF-induced activation of NFκB, an important pathway in 
cell survival [182, 190]. 
 DAB2IP further tips the scales in favor of apoptosis over survival by 
inhibiting the PI3K-AKT pathway [165]. AKT negatively regulates ASK1 by 
phosphorylation at S83 [191]. PI3K-AKT is also an important positive regulator of 
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NFκB [192]. DAB2IP inhibits AKT by preventing its phosphorylation at S473[165]. 
This is mediated by inhibitory interactions between DAB2IP and both AKT and the 
p85 regulatory subunit of PI3K [165, 167]. 
 
1.4.2.2. DAB2IP restrains EMT and metastasis 
 
 The initial characterization of DAB2IP revealed that its overexpression in 
metastatic prostate cancer cells could suppress their growth in culture [18]. At that 
time, it was speculated that DAB2IP played a role in metastatic prostate cancer. It 
has since been firmly established that DAB2IP is an important regulator of EMT 
and metastasis in multiple cancers [166, 193-197]. 
 Regulation of EMT and metastasis by DAB2IP occurs through simultaneous 
inhibition of Ras-Raf-MEK-ERK and PI3K-AKT-NFκB signaling pathways [167]. 
Using a combination of in vitro and in in vivo techniques, it was demonstrated that 
DAB2IP-mediated suppression of EMT and tumor initiation was a result of GTPase 
activity, whereas inhibition of metastasis was caused by NFκB suppression [167]. 
NFκB suppression by DAB2IP here was mediated by the same mechanisms 
described in 1.4.2.1. 
 DAB2IP also inhibits metastasis through suppression of Wnt/β-catenin 
signaling. Wnt is frequently activated in cancer [198]. Canonical Wnt signaling 
involves stabilization of the transcriptional activator β-catenin [199]. DAB2IP 
suppresses this pathway by recruiting PP2A to the kinase GSK-3β [200]. 
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Dephosphorylation of GSK-3β at S9 is activating, allowing it to phosphorylate β-
catenin and target it for degradation [201].  
 
1.4.2.3. DAB2IP suppresses inflammatory angiogenesis 
 
 DAB2IP knockout mice were generated in 2008 to investigate the function 
of the protein in vivo. It was discovered that DAB2IP was key regulator of 
inflammatory angiogenesis [164]. The initial report demonstrated suppression of 
VEGFR and AKT activation caused by DAB2IP, and that GAP activity on Ras was 
not responsible for AKT inhibition. Instead, DAB2IP was found to bind directly to 
the VEGFR2-PI3K complex and prevent VEGFR2-mediated activation of PI3K. 
However, Ras does still activate PI3K, and Ras and NFκB signaling are linked 
[202]. Thus it appears, that the regulatory roles of DAB2IP are tightly interweaved, 
and the importance of DAB2IP in disease is due to concomitant deregulation of all 






Materials and Methods 
 
2.1.  Plasmids 
 
pCDNA3-HA-RASSF1A – pcDNA3-HA-RASSF1A was described previously [152]. 
pcDNA™3.1 mammalian expression vector was purchased from Invitrogen (Cat. 
#V79020). This vector was modified to express a fused hemagglutinin (HA) epitope 
tag by Dr. Geoffrey Clark. The full length RASSF1A coding sequence was cloned 
from pcDNA3.1-RASSF1A into pcDNA3-HA as a BamHI/NotI restriction fragment.  
 
KATE-RASSF1A – pmKate2-C-RASSF1A has been described previously [10]. 
The BamHI/EcoR1 restriction fragment from pcDNA3-HA-RASSF1A was cloned 
in to the pmKate2-C vector (Evrogen, Moscow, Russia, Cat. #FP181). 
 
K-RASG12V – pCGN-KRASG12V was described previously [204]. 
 
GFP-DAB2IP – pEGFP-DAB2IP was a gift from Dr. Karen Cichowski (Harvard). 
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shRASSF1A – pBRS-shRASSF1A was generated by cloning the shRNA 
sequence from pRS-RASSF1A 777 (Origene, Cat. #TR307696) into the pGFP-B-
RS vector (Origene, Cat. #TR30018). 
 
shDAB2IP – pGIPZ-shDAB2IP was a generous gift from Jer-Tsong Hsieh (UT 
Southwestern) [205]. 
 
2.2. Cell lines 
 
HEK-293T – Human Embryonic Kidney 293 T (HEK-293T) cells were purchased 
from the ATCC. These cells are modified with the SV40 Large T-antigen, allowing 
for enhanced protein expression. This cell line is easy to transfect and is therefore 
useful in overexpressed co-immunoprecipitation studies. HEK-293T cells were 
maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (pen/strep). 
 
COS-7 – COS-7 (CV-1 in Origin with SV40 genes) cells were purchased from the 
ATCC. These fibroblast-like cells are derived from the African green monkey 
(Cercopithecus aethiops) kidney cells. Morphologically, these cells are large and 
flat, making them particularly useful for imaging fluorescently tagged proteins. 
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NCI-H1299 – These cells were purchased from the ATCC. H1299 is a non-small 
cell lung carcinoma line derived from the lymph node of a 43-year-old Caucasian 
male. This line harbors a Q61K mutation in the NRAS gene. It is also p53-null, 
resulting from a homozygous partial deletion of TP53. Additionally, these cells 
have lost endogenous expression of RASSF1A [206]. H1299 cells were 
maintained in RPMI 1640 medium (RPMI) supplemented with 10% FBS and 1% 
pen/strep. 
 
NCI-H1792 – NCI-H1792 cells were purchased from the ATCC. This is a stage 4 
non-small cell lung adenocarcinoma cell line derived from the pleural effusion of a 
50-year-old Caucasian male. It harbors a G12C mutation in the KRAS gene [115]. 
NCI-H1792 cells were maintained in RPMI supplemented with 10% FBS and 1% 
pen/strep 
 
NCI-H1437 – H1437 cells were purchased from the ATCC. This is a stage 1 non-
small cell lung adenocarcinoma cell line derived from the pleural effusion of a 60-
year-old Caucasian male. H1437 cells were maintained in RPMI supplemented 
with 10% FBS and 1% pen/strep. H1437 cells retain wild-type Ras expression 
[207]. 
 
MCF-10A – MCF-10A breast epithelial cells were purchased from the ATCC. This 
is an immortalized, non-transformed epithelial cell line derived from the mammary 
gland of a 36-year-old Caucasian female [208]. As a non-tumorigenic line, MCF-
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10A cells have not undergone hypermethylation of the RASSF1A promoter, 
making them a useful tool for RASSF1A co-immunoprecipitation studies. MCF-10A 
cells were maintained in DMEM/F12 50:50 mix supplemented with 5% horse 
serum, 20 ng/mL epidermal growth factor (EGF), 0.5 μg/mL hydrocortisone, 10 
μg/mL insulin, and 1% pen/strep. 
 
2.3. Cell culture, treatment, and genetic manipulation 
 
2.3.1. Cell culture 
   
Growth Media – Cell lines used in this work were maintained in conditions 
recommended by the ATCC. All growth media were purchased from Corning. 
DMEM (Cat. #10-013-CV) and contains L-glutamine, sodium pyruvate, and 4.5 g/L 
glucose. DMEM was supplemented with 10% FBS (Corning, Cat. #35-010-CV) and 
1% penicillin/streptomycin (Corning, Cat. #30-002-CI). RPMI 1640 (Cat. #10-040-
CV) contains L-glutamine and was supplemented with 10% FBS and 1% pen/strep. 
DMEM/F12 50:50 Mix (Cat. #15-090-CV) is a 50:50 mixture of DMEM and Ham’s 
F12 medium. It contains L-glutamine and was supplemented with 5% horse serum 
(Gibco, Cat. #26050-07), 20 ng/mL EGF (Gibco, Cat. #PHG0311), 0.5 μg/mL 
hydrocortisone (Sigma, Cat. #H0888), 10 μg/mL insulin (Sigma, Cat. #I92780-
5ML), and 1% pen/strep. 
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Passaging – Trypsin-EDTA (0.25%) was purchased from Corning (Cat. #25-053-
CI) and was used to remove adherent cells from culture vessels. Culture medium 
was aspirated and cells were washed once with sterile 1X phosphate-buffered 
saline (PBS) (Corning, Cat. #21-040-CM). The PBS was aspirated, then trypsin-
EDTA was applied to the cells and incubated at 37ºC for several minutes until cells 
were detached from the culture vessel. Trypsin was neutralized with complete 
medium (containing FBS) and cells were collected via centrifugation at 1500 rpm 
for 5 minutes. The resulting supernatant was aspirated and the cells were 
resuspended in complete medium and plated as needed.  
 
2.3.2. Chemicals for cell treatment 
  
 To elucidate mechanisms of protein stabilization we treated cells with 
various inhibitors. MG-132 (Selleckchem, Cat. #S2619) is a reversible proteasome 
inhibitor. MG-132 powder was reconstituted in DMSO (Sigma, Cat. #D2438) at a 
stock concentration of 50 mM and diluted in culture media to a final concentration 
of 50 μM. In these experiments, cells were treated with MG-132 for 4 hours prior 
to lysis. Chloroquine (Sigma, Cat. #C6628) is an anti-malarial medication that is 
used in cell culture to inhibit the lysosome. Chloroquine powder was dissolved in 
DMSO to a stock concentration of 50 mM and diluted in complete media to a final 
concentration of 50 μM. In these experiments, cells were treated with chloroquine 
for 24 hours prior to lysis. Cycloheximide (Sigma, Cat. #7698) is an inhibitor of 
protein synthesis. Cycloheximide powder was dissolved in ethanol (Sigma, Cat. 
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#E7023) to a stock concentration of 20 mg/mL and diluted in complete media to a 
final concentration of 20 μg/mL. Cells were treated for 0, 2, 4, and 8 hours prior to 
lysis. 
 
2.3.3. Transfection reagents 
 
jetPRIME® – The jetPRIME® DNA/siRNA transfection reagent is manufactured by 
Polyplus Transfection (Illkirch, France, Cat. #114-07) and can be purchased from 
VWR (Cat. #89129-922). jetPRIME® was primarily used for transient transfections. 
1 μg of each plasmid DNA construct to be transfected was diluted in 200 μL of 
jetPRIME® transfection buffer, provided by the manufacturer, and vortexed briefly. 
To this, 2 μL of jetPRIME® was added per microgram of DNA. The mixture was 
then vortexed for 10 seconds, spun down for 10 seconds, then incubated at room 
temperature for 10 minutes. After incubation, the mixture was added dropwise to 
cells in a 60 mm culture dish, evenly dispersed by gentle rocking, and incubated 
for 16 hours at 37ºC. This reaction can be scaled for culture vessels of different 
sizes. Also, if cytotoxicity is observed, the 37ºC incubation can be performed for 6-
8 hours, followed by overnight incubation in fresh complete medium. 
 
Lipofectamine™ 3000 – Lipofectamine™ 3000 (Invitrogen, Cat. #L3000008) is a 
lipid nanoparticle-based transfection reagent designed for cells that are difficult to 
transfect using other transfection reagents such as jetPRIME®. NCI-H1792, NCI-
H1437, and NCI-H1299 cells were transfected using Lipofectamine 3000® 
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according to the manufacturer’s protocol for generation of stable knockdown cell 
lines. For these transfections, 2-5 μg of plasmid DNA and 2 μL of P3000™ reagent 
(provided by the manufacturer) were diluted in 125 μL Opti-MEM reduced serum 
media (Gibco, Cat. #31985070), briefly vortexed, and spun down for 2-3 seconds. 
7.5 μL of Lipofectamine ™ 3000 reagent was diluted in another 125 μL of Opti-
MEM, briefly vortexed, and spun down. 125 μL of each mixture was combined and 
incubated at room temperature for 10 minutes. The mixture was then added 
dropwise to one well of cells in a 6-well plate and incubated at 37ºC for 24 hours. 
Fresh media was then applied and the cells were incubated for an additional 24 
hours prior to antibiotic selection. 
 
2.3.4. Lysis buffers 
 
 Co-immunoprecipitation reactions require cell lysis to be performed in 
buffers that can disrupt the plasma membrane while leaving intact cytoplasmic 
protein-protein interactions. For this purpose, a modified RPIA buffer (NP-40 
buffer) was used. This buffer consists of 50 mM Tris-HCl pH 7.5 200 mM NaCl, 
and 1% Tergitol™ Type NP-40 (Sigma, Cat. #NP40). Cell lysates that did not 
require preservation of protein-protein interactions were prepared in RIPA buffer 
(Sigma, Cat. #R0278), which contains 150 mM NaCl, 1.0% IGEPAL® CA630, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), and 50 mM Tris 
pH 8.0. Lysates for Active Ras pulldown assays were prepared in Active Ras 
Pulldown Cell Lysis Buffer provided by the manufacturer (Cytoskeleton, Cat. 
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#BK008). It contains 50 mM Tris pH 7.5, 10 mM MgCl2, 0.5 M NaCl, and 
2%IGEPAL® CA630. All lysis buffers were prepared fresh at time of cell lysis and 
supplemented with Protease Inhibitor Cocktail (Sigma, Cat. #P8340), 1 mM 
Na3VO4, and 1 mM NaF. 
 
2.4. Molecular Biology 
 
 During the course of this work, multiple plasmid constructs were used to 
confirm a novel protein-protein interaction and characterize its function. 
Overexpressed co-immunoprecipitations, fluorescent co-localization studies, and 
shRNA knockdown of endogenous proteins all employ the use of plasmid DNA 
constructs that can be propagated and purified from competent E. coli. 
 
2.4.1. Bacterial transformation 
 
 Chemically competent DH5α cells were purchased from Invitrogen (Cat. 
#18261-017). For bacterial transformation, approximately 100 ng of whole plasmid 
was mixed with 30 μL DH5α bacteria and incubated on ice for 30 minutes. The 
bacteria were subjected to a 42ºC heat shock for 45 seconds, allowing DNA to 
enter through pores in on the bacterial surface. This was followed by another 2-
minute incubation on ice. 200 μL of SOC media (Corning, Cat. #46-003-CR) was 
added to the mixture and incubated at 37ºC for 1 hour. Following this, bacteria 
were gently resuspended and 100 μL of this suspension was streaked on to LB 
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agar plates [2% LB Base (Invitrogen, Cat. #12780052), 1% Select Agar (Invitrogen, 
Cat. #30391023)] containing the appropriate antibiotic based on the bacterial 
resistance marker of the plasmid. For these experiments, the antibiotic used was 
either Ampicillin (Sigma, Cat. #A9518) at a concentration of 100 μg/mL, or 
Kanamycin sulfate (Calbiochem, Cat. #420331) at a concentration of 50 μg/mL. 
Plates were incubated, inverted, overnight at 37ºC. 
  
2.4.2. Plasmid purification 
 
 Following transformation, individual colonies were picked from the LB agar 
plates and grown in 5 mL a sterilized 2% solution of LB Base in water containing 
the appropriate antibiotic, using a shaking incubator at 37ºC, 300 RPM. 5 mL 
cultures were grown overnight and immediately used for DNA Plasmid Mini-Prep 
(Qiagen, Cat. #27106), or used to inoculate 100 mL cultures for Midi-Prep (Qiagen, 
Cat. #12145; Sigma, Cat. #NA0200-1KT). Both DNA preparations were performed 
according to the manufacturer’s protocol. Briefly, they involve lysis of the bacterial 
membrane followed by precipitation and pelleting of bacterial genomic DNA. 
Plasmid DNA is bound to a column, proteins and RNA are washed away, and 
plasmid DNA is finally eluted from the column. DNA concentration was determined 
using a NanoDrop™ 8000 Spectrophotometer (Thermo Scientific, Cat. #ND-8000-
GL). 
 
2.4.3. Generation of stable RASSF1A and DAB2IP knockdown lines 
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 In order to characterize the interaction between RASSF1A and DAB2IP, we 
generated matched sets of NCI-H1792 and NCI-H1437 cells that were either wild-
type or stably knocked down for DAB2IP and/or RASSF1A. We also generated a 
matched set of NCI-H1299 cells in which DAB2IP was knocked down and 
RASSF1A was overexpressed. 
 Knockdown of RASSF1A in NCI-H1792 cells was described previously [11]. 
Briefly, an shRNA against RASSF1A was cloned into the pSM2 vector and 
transfected into NCI-H1792 cells. Cells were then selected in puromycin. pGIPZ 
and pSM2 both contain puromycin resistance markers, so lentiviral infection was 
used by Dr. Howard Donninger to knockdown DAB2IP these cells. To generate 
DAB2IP knockdown cells, 293FT cells were transfected with pGIPZ-shDAB2IP 
(see section 2.1) and viral packaging plasmids pLP1, pLP2, and pLP/VSVG 
(Invitrogen) at a ratio of 1:3 using jetPRIME® transfection reagent. 48-72 hours 
after transfection, growth medium containing viral particles was harvested and 
clarified by centrifugation at 2 krpm for 5 minutes. 2 mL of the clarified viral 
supernatant supplemented with 5 μg/mL polybrene was applied to NCI-H1792 
cells overnight at 37ºC. Fresh medium was applied to the 293FT cells and the viral 
transduction was performed two additional times. After transduction, GFP-positive 
cells (which express GFP from stable incorporation of the DAB2IP shRNA) were 
selected using a MoFlo XDP Cell Sorter (Beckman Coulter). 
 Stable knockdown of DAB2IP and RASSF1A in NCI-H1437 cells was 
achieved by Lipofectamine™ 3000 transfection followed by antibiotic selection. 
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pGIPZ-shDAB2IP was transfected into NCI-H1437 cells. 48 hours after 
transfection, cells were selected in 1.5 μg/mL puromycin (Sigma, Cat. #8833-
10MG). Stable transfectants were expanded and assayed/frozen as an early 
passage pooled population of cells. H1437-shDAB2IP and control cells were then 
transfected with pBRS-shRASSF1A 777 in a similar fashion, and selected in 6 
μg/mL blasticidin (Sigma, Cat. #15205-25MG).  
 Stable re-expression of HA-RASSF1A in NCI-H1299 cells was described 
previously [148]. Briefly, 1 μg of pZip-neoHA-RASSF1A was transfected into 
H1299 cells using Lipofectamine™ 2000, a precursor to Lipofectamine™ 3000. 
Stable transfectants were selected in 500 μg/mL G4138 sulfate. Knockdown of 
DAB2IP in these cells was achieved in the same manner as in H1437 cells (see 
above). For each stably expressed shRNA or tagged expression construct, a 
stable line expressing an empty vector was generated to create a matched set of 
four lines that are +/+, +/–, –/+, and –/– for RASSF1A/DAB2IP expression, 
respectively, in each lung cancer cell line. 
 
2.5. Biological assays 
 
 Confirming and characterizing a novel protein binding interaction requires 
the use of many biological techniques. Some of the assays employed in this work 
to test the hypotheses established herein are technically involved and are 
performed over the course of several days or weeks. In vitro and in vivo growth 
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assays and Western blot analysis of signaling pathways were utilized in this work. 
A detailed account of how these assays were performed is provided below. 
 
2.5.1. Growth assays 
 
 A classical method of measuring the tumor suppressive ability of a protein 
is to assay its ability to restrict the growth of cultured cancer cells. There are 
multiple growth assays that will provide differing degrees of physiological 
relevance. Generally, the degree of relevance of a particular result is a dependent 
on the amount of stress applied to the cell in the course of the assay. For example, 
enhanced in vitro 2D growth in response to RASSF1A loss implicates RASSF1A 
as a suppressor of growth. Enhanced anchorage-independent growth or, better, 
enhanced xenograft growth in response to RASSF1A loss more clearly 
demonstrates the importance of RASSF1A in tumor suppression as it highlights 
the heartiness of RASSF1A-deficient cells and their ability to survive unfavorable 
conditions. In this investigation, two growth assays were used: a 2D growth curve 
and a subcutaneous xenograft growth curve. 
 
2.5.1.1. 2D growth curves 
 
 2D growth curves were performed in triplicate in 6-well plates. For each cell 
line, 104 cells in log phase growth were plated in 9 wells of 6-well plates. 24 hours 
after plating, 3 wells were trypsinized, pelleted, resuspended in complete growth 
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medium, and counted on a hemocytometer. 3 wells were again counted on days 3 
and 7. 
 
2.5.1.2. Xenograft growth curves 
 
Immunodeficient mice can be used to measure the in vivo effects of a 
protein on tumor formation. To identify differences in in vivo growth of the matched 
sets of knockdown cells, each cell line was seeded at low density in several T75 
flasks and allowed to propagate for 3 days to reach log phase growth. Cells were 
trypsinized, pelleted, and washed twice in 1X PBS by resuspension and re-
pelleting. Cells were finally resuspended at a concentration of 10 x 106 cells/mL in 
1X PBS and placed on ice. For each cell line 6 NRG mice were anesthetized with 
isoflurane and 100 μL of cell suspension containing 1 x 106 cells was injected 
subcutaneously into the left flank. Animals were monitored and tumor length and 
width measurements were taken with calipers. Tumor volume was calculated using 
the formula 𝑉 = #×%
&
'
. When the first tumors reached a diameter at 1.5 cm, all 
animals were sacrificed and tumors were harvested and snap frozen in liquid 
nitrogen. 
 
2.5.2. Western blot analysis 
 
 Western blotting was performed under reducing conditions. For this, 450 μL 
4X LDS sample buffer (Invitrogen, Cat. #NP0007) was mixed with 50 μL of 2-
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mercaptoethanol and stored in an amber microcentrifuge tube. Washed IP beads 
resuspended in RIPA buffer and whole cell lysates were combined with prepared 
LDS buffer and vortexed thoroughly to mix. Tubes were boiled at 95ºC for 10 
minutes to denature proteins, then spun down briefly to collect condensation on 
the tube lids. Samples were loaded onto a precast NuPAGE™ 4-12% Bis-Tris 
polyacrylamide gel (Invitrogen, Cat. #NP0321BOX, NP0322BOX, NP0336BOX). 
Electrophoresis was performed at 120V in 1X NuPAGE™ MOPS SDS Running 
buffer (Invitrogen, Cat. #NP0001) until the dye front reached the bottom of the gel. 
 Resolved proteins were transferred to a 0.2 μm pore nitrocellulose 
membrane (Invitrogen, Cat. #LC2009) using complete immersion (wet) transfer in 
1X Transfer Buffer (5% NuPAGE™ Transfer Buffer (20X) (Invitrogen, Cat. 
#NP00061), 20% methanol, 75% DI water). Transfer buffer was cooled prior to 
use. Transfers were performed using the Mini Blot Module (Life Technologies, Cat. 
#B1000) at 10V for at least 3 hours. 
 After transferring, membranes were blocked for 1 hour in a 5% solution of 
non-fat dry milk in TBS-T. Membranes would then be washed twice for 2 minutes 
in TBS-T, then incubated with primary and secondary antibody as described in 
section 2.5.2.1. After each antibody incubation, membranes were washed 3 times 
for 5 minutes in TBS-T before continuing to the next incubation. After the 
secondary incubation, a fourth wash of 10 minutes in TBS-T was performed to 
ensure minimal background detection. Blots were then immersed in West Pico 
PLUS solution for 5 minutes. Bands were detected using chemi-luminescent 
detection film (MidSci™, Cat. #EBA45). 
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2.5.2.1.  Antibodies 
 
Hemagglutinin (HA) – Mouse α-HA monoclonal antibody was purchased from 
Covance (Cat. #MMS-101P). For detection of HA-tagged proteins, the antibody 
was diluted at 1:10,000 in a 5% solution of non-fat dry milk in Tris-buffered saline 
with Tween-20(TBS-T: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween-20). 
Membranes were incubated in primary antibody overnight at 4ºC with constant 
agitation, then in HRP-linked α-mouse secondary antibody (Cell Signaling 
Technology, Cat. #7076S) at a dilution of 1:10,000 in TBS-T for 1 hour at room 
temperature with constant agitation. Detection was performed using 
SuperSignal™ West Pico PLUS Chemi-Luminescence substrate (Thermo 
Scientific, Cat. #34579).  
 
Green fluorescent protein (GFP) – Mouse α-GFP (B2) monoclonal antibody was 
purchased from Santa Cruz Biotechonology (Cat. #sc-9996). For detection of GFP-
tagged proteins, the antibody was diluted at 1:200 in a 5% solution of non-fat dry 
milk in TBS-T. Membranes were incubated in primary antibody overnight at 4ºC 
with constant agitation, then in HRP-linked α-mouse secondary antibody at a 
dilution of 1:10,000 in TBS-T for 1 hour at room temperature with constant 
agitation. Detection was performed using West Pico PLUS.  
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Phospho-S473 AKT – The Ser/Thr kinase AKT is phosphorylated at S473 in 
response to activation by Ras. Phosphorylation of AKT at S473 serves as a 
measure of Ras activity. Endogenous phosphorylated AKT was detected using a 
rabbit α-P-S473AKT polyclonal antibody (Cell Signaling Technology, Cat. 
#4060S). The antibody was diluted at 1:1,000 in a 5%s solution of BSA in TBS-T. 
Membranes were incubated overnight at 4ºC with constant agitation, then in HRP-
linked α-rabbit secondary antibody at a dilution of 1:10,000 in TBS-T for 1 hour at 
room temperature with constant agitation. Detection was performed using West 
Pico PLUS. 
 
AKT - Endogenous AKT was detected using a rabbit α-P-S536 NFκB p65 
polyclonal antibody (Cell Signaling Technology, Cat. #9272S). The antibody was 
diluted at 1:1,000 in a 5%s solution of BSA in TBS-T. Membranes were incubated 
overnight at 4ºC with constant agitation, then in HRP-linked α-rabbit secondary 
antibody at a dilution of 1:10,000 in TBS-T for 1 hour at room temperature with 
constant agitation. Detection was performed using West Pico PLUS. 
 
Phospho-ERK – Extracellular signal-regulated kinase 1/2 (ERK 1/2) is the terminal 
effector of the Ras-Raf-MEK-ERK pathway. Upon activation, ERK 1/2 are 
phosphorylated on T202 and Y204, respectively. Endogenous phosphorylated 
ERK 1/2 were detected using a rabbit α-P-T202/Y204 ERK antibody (Cell 
Signaling Technology, Cat. #9101S). The antibody was diluted at 1:1,000 in a 5% 
solution of BSA in TBS-T. Membranes were incubated overnight at 4ºC with 
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constant agitation, then in HRP-linked α-rabbit secondary antibody at a dilution of 
1:10,000 in TBS-T for 1 hour at room temperature with constant agitation. 
Detection was performed using West Pico PLUS. 
 
ERK – Endogenous ERK 1/2 was detected using a rabbit α-ERK 1/2 polyclonal 
antibody (Cell Signaling Technology, Cat. #9102S). The antibody was diluted at 
1:1,000 in a 5% solution of BSA in TBS-T. Membranes were incubated overnight 
at 4ºC with constant agitation, then in HRP-linked α-rabbit secondary antibody at 
a dilution of 1:10,000 in TBS-T for 1 hour at room temperature with constant 
agitation. Detection was performed using West Pico PLUS. 
 
DAB2IP – Endogenous DAB2IP was detected using a mouse α-DAB2IP 
monoclonal antibody (Aviva Systems Biology, Cat. #OAAL00940). The antibody 
was diluted at 1:1,000 in a 5% solution of non-fat dry milk TBS-T. Membranes were 
incubated overnight at 4ºC with constant agitation, then in HRP-linked α-mouse 
secondary antibody at a dilution of 1:10,000 in TBS-T for 1 hour at room 
temperature with constant agitation. Detection was performed using West Pico 
PLUS. 
 
RASSF1A – Endogenous RASSF1A was detected using a mouse α-RASSF1 
(3F3) monoclonal antibody (Abcam, Cat. #ab23950). The antibody was diluted at 
1:200 in a 5% solution of non-fat dry milk in TBS-T. Membranes were incubated 
overnight at 4ºC with constant agitation, then in HRP-linked α-mouse secondary 
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antibody at a dilution of 1:2000 in TBS-T for 1 hour at room temperature with 
constant agitation. Detection was performed using West Pico PLUS. Expression 
of RASSF1A is often suppressed in cancer, making endogenous RASSF1A protein 
difficult to detect in some cell lines. To increase sensitivity, West Pico PLUS was 
supplemented with SuperSignal™ West Femto Maximum Sensitivity Substrate 
(Thermo Scientific, Cat. #34094) at concentration of 10-15%, as needed.  
 
TrueBlot® Mouse Secondary – For co-immunoprecipitation experiments, the 
primary antibodies used to detect endogenous protein were of the same species 
as conjugated antibody used in the agarose immunoprecipitation beads. This leads 
to detection of IgG heavy and light chain bands that may obscure bands of interest 
on Western blots. To avoid this, a TrueBlot® mouse secondary was used 
(Rockland Inc., Cat. #18-8817-33), which does not detect IgG chains. TrueBlot 
mouse secondary was diluted at 1:1,000 in a 5% solution of non-fat dry milk. 
Incubation and detection were performed as with the standard mouse secondary 
antibody. 
  




 Co-immunoprecipitation (Co-IP) is a widely-used technique for investing 
protein-protein interactions in cells. In this technique a protein of interest is bound 
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by an antibody, and the protein-antibody complex is precipitated using beads, 
typically made of agarose, that bind to the Fc region of the antibody. In the case of 
exogenous tagged proteins, antibody pre-conjugated to agarose is commercially 
available to simplify the protocol. Whatever the case, the use of mild detergents in 
the lysis buffer is critical, as strong detergents like SDS readily disrupt protein-
protein interactions. This assay is straightforward in principle; however, the length 
of the assay and the multiple binding interactions that must be maintained ex-vivo 
for multiple days makes successful co-immunoprecipitation quite difficult to 
achieve, particularly for endogenous proteins that are expressed in low 
abundance. 
  
2.6.1.1. Immunoprecipitation of overexpressed proteins 
 
 In this work, HEK-293T cells were transfected in 60 mm dishes 24 hours 
prior to lysis. Cells were scraped in an appropriate volume of NP-40 buffer, typically 
350 μL, and transferred to a microcentrifuge tube. Cell suspensions were placed 
on a rotator and incubated at 4ºC for 4 hours. The lysates were passed through a 
21 ga needle five times, then centrifuged at ≥ 14 krpm for 5 minutes at 4ºC. The 
supernatants were reserved and immediately placed on ice; the pellets were 
discarded. The protein concentrations of the lysates were determined using the 
Bio-Rad protein quantification assay (Cat. #5000006). 1 mg of whole cell lysate 
was used per immunoprecipitation (500 μg if there was insufficient volume for 1 
mg) and brought to a volume of 1 mL with NP-40 buffer in microcentrifuge tubes. 
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5 μL of GFP-nAb™ agarose (Allele Biotechnology, Cat. #ABP-nAb-GFPA025) was 
added to each tube. Samples were placed on a rotator and incubated at 4ºC 
overnight. The next day, the beads were pelleted by centrifugation at 3 krpm, 4ºC 
for 3 minutes. The supernatant was aspirated and the beads were washed with 
500 μL of NP-40 buffer. This was repeated two additional times. After the third 
wash was aspirated, beads were resuspended in 10 μL RIPA buffer and 4 μL 
NuPAGE™ LDS Sample Buffer (Invitrogen, Cat. #NP0007). IPs and 30 μg of whole 
cell lysate were resolved on SDS-PAGE gels and analyzed as described in section 
2.5.2. 
 
2.6.1.2.  Immunoprecipitation of endogenous proteins 
 
 Endogenous proteins are immunoprecipitated using antibodies that 
recognize three-dimensional epitopes on the surface of the protein. Therefore, not 
all antibodies that recognize a protein on a Western blot, where the protein has 
been denatured, are appropriate for immunoprecipitation. In this particular 
experiment, the precipitated protein, RASSF1A, is endogenously expressed at low 
levels, and therefore large quantities of protein are needed for 
immunoprecipitation. This can be challenging using mild detergents like NP-40; 
however, such detergents are required for this assay and thus other steps were 
taken to maximize protein yield. Multiple 10 cm dishes were growth to 
confluence and scraped into a small volume of NP-40, typically 500 μL for 2 dishes. 
The cell suspension was placed on a rotator and incubated at 4ºC for 8 hours. The 
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lysate was then passed through a 21 ga needle 5 times and centrifuged at ≥ 14 
krpm, 4ºC for 10 minutes. The supernatant was transferred to a new 
microcentrifuge tube and centrifuged again if needed to obtain a clear lysate. 
Protein concentration was again determined using the Bio-Rad protein 
quantification assay.8 mg of whole cell lysate was aliquoted into two 
microcentrifuge tubes (4 mg per tube) and each was diluted to a final volume of 1 
mL. 1 mL of NP-40 buffer was added to a third tube. The buffer tube and one of 
the lysate tubes served as negative controls. To one lysate-containing tube and 
the buffer only tube, the immunoprecipitation antibody was added. NP-40 buffer 
was added to remaining tube as a blank. All tubes were placed on a rotator and 
incubated at 4ºC overnight. The next morning, 20 μL of TrueBlot® IP beads 
(Rockland Inc., Cat. #00-8800-25) were added to each tube, and tubes were 
rotated at 4ºC for 2 hours. The beads were washed three times with NP-40 buffer 
and resuspended as described in section 2.6.1.1. 
 
2.6.2. Active Ras pulldown assay 
 
 Analysis of downstream signaling activity is a useful method of determining 
the activation state of a particular protein if downstream targets are known and 
reagents to detect their activation are available. In cancer, however, such a method 
can often lead to inconclusive results. First, the complex networks involved in cell 
signaling result in effector proteins usually having multiple upstream regulators, 
and so the activity of an effector may not be readily attributable to the regulator of 
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interest. Indeed, this is the case in homeostatic tissue as well. Additionally, a 
hallmark of cancer is dysregulation of cell signaling. Mutations or other disruption 
in different parts of a particular pathway may obscure the activity of the protein of 
interest. Thus, a method of directly measuring the activation state of a protein is 
favorable when possible.  
 Fortunately, since Ras is a small GTPase whose binding affinity depends 
on its activation state, the degree of activation of Ras can be determined directly 
by precipitating the active GTP-bound form of Ras using an exogenously 
expressed Ras Binding Domain (RBD) conjugated to agarose beads. The Active 
Ras Pulldown Kit (Cytoskeleton, Cat. #BK008) was used to perform this assay 
according to the manufacturer’s protocol. 10 cm dishes of each cell line were 
seeded at 5 x 105 cells per dish and incubated for 72 hours to achieve log phase 
growth. Cells were then washed once with ice-cold 1X PBS and scraped, on ice, 
into Cell Lysis Buffer provided by the manufacturer (see section 2.4.4). Cell 
suspensions were transferred to microcentrifuge tubes and were passed through 
a 21 ga needle five times, then centrifuged at 10 krpm for 10 minutes. After 
centrifugation, the supernatants were transferred to clean microcentrifuge tubes. 
30 μL of each lysate was aliquoted for protein quantification using the Pierce™ 
BCA Protein Assay (Thermo Scientific, Cat. #23225). The remaining lysates were 
snap frozen in liquid nitrogen to prevent GTP hydrolysis. After quantification, 
lysates were thawed in a room temperature water bath and immediately placed on 
ice. 500 μg of whole cell lysate was diluted to a final volume of 500 μL, and 10 μL 
Raf-RBD agarose beads were added to each sample. Samples were placed on a 
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rotator and incubated at 4ºC for 1 hour. Beads were pelleted by centrifugation at 
3,000 x g, 4ºC for 1 minute. The -supernatants were aspirated, then beads were 
washed once with 500 μL of Wash Buffer provided by the manufacturer. Beads 
were again pelleted by centrifugation at 5,000 x g, 4ºC for 3 minutes. The Wash 
Buffer was aspirated and the beads were resuspended in 10 μL RIPA buffer and 
4 μL LDS Sample Buffer. IPs and 30 μg whole cell lysate were resolved on SDS-









 Ras is the most frequently activated oncogene in human cancer, with point 
mutations occurring in approximately 30% of all tumors [27]. Experimentally, 
mutant Ras has been shown repeatedly to rapidly transform cultured cells [209-
211]. Upon activation, Ras binds multiple downstream mitogenic effectors, whose 
activities synergize to confer potent transforming abilities to Ras. The three best 
characterized mitogenic effectors are Raf, PI3K, and RalGDS [212]. For decades, 
attempts have been made to target the Ras proteins therapeutically as a treatment 
for cancer, and for decades those attempts have failed [213]. That is, until very 
recently. Several reports in the past five years have revealed a previously unknown 
characteristic of a particular Ras mutant. In the course of developing covalent 
inhibitors of K-RasG12C, it was demonstrated that this mutant actively undergoes 
GTP-GDP cycling in tumors, and these inhibitors work by trapping the Ras mutant 
in the GDP-bound state [116]. 
While Ras can transform immortalized cells, it invokes apoptosis and 
premature senescence in primary cells [8, 214]. Much about this paradoxical 
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growth inhibitory nature of Ras remains to be discovered; however, the RASSF 
family of tumor suppressors has been implicated in mediating these effects, 
particularly RASSF1A [9, 127]. In order to induce transformation, Ras requires 
cooperating mutations, such as deletion of p53 or activation of MYC [215-217]. 
This aids Ras-mediated transformation in part by blocking apoptosis/senescence 
in response to Ras hyperactivation [218, 219]. Similarly, loss of RASSF1A 
expression, a frequent event in human cancer primarily caused by promoter 
hypermethylation, has also been shown to contribute to Ras-mediated 
transformation [14, 127, 131]. RASSF1A binds Ras directly and induces apoptosis 
in a GTP-dependent manner [11, 122]. Mechanisms of RASSF1A-induced growth 
arrest are not fully described, but among the best characterized RASSF1A 
effectors are the Hippo kinases MST1/2 and Bax, an inducer of mitochondrial 
apoptosis. 
RASSF1A lacks apparent enzymatic activity, instead functioning as a 
scaffold. Upon Ras activation, RASSF1A bind Ras-GTP and connects it to 
modulator of apoptosis-1 (MOAP-1) [11], or the MST kinases [220], activating them 
and subsequently inducing apoptosis through Bax or the transcriptional activator 
YAP, respectively [11, 138, 141, 145, 146, 220, 221]. Thus, the frequent loss of 
RASSF1A in cancer, considered an early/premalignant lesion [130, 222, 223], 
permits Ras-mediated transformation by uncoupling Ras from its apoptotic effector 
pathways. However, this is not the full extent of deregulation caused by loss of 
RASSF1A expression. Indeed, multiple groups have reported upregulation of Ras 
mitogenic signaling, including Raf-Mek-Erk, PI3K-AKT, and RalGDS-Ral, upon 
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downregulation of RASSF1A in vitro and in vivo [13, 14, 17]. Collectively, this work 
lends itself to the tantalizing possibility of a feedback inhibition activity of RASSF1A 
on Ras, an exceedingly common mechanism of protein inhibition generally, but 
one that has not yet been described for Ras [37]. 
RASSF1A has been shown previously to modulate the activation on AKT 
and Raf; however, the ultimate effect of these interactions is unclear. Raf can bind 
to the Hippo kinase MST2 and inhibit its activation [224]. However, this interaction 
also inhibits Raf by preventing its activation by Ras [16]. RASSF1A and Raf 
compete for binding with MST2, and disruption of the Raf-MST2 complex is 
required for RASSF1A-MST2-induced apoptosis [138]. This suggests that the 
RASSF1A-MST2 interaction would serve to counterintuitively activate Ras-Raf-
Mek-Erk [9]. Raf activity is regulated by phosphorylation, and S259 is an inhibitory 
residue. Phosphorylation of Raf at S259 is mediated by AKT and enhances its 
reciprocally inhibitory association with MST2 [225]. AKT also phosphorylates 
MST2, which enhances its interaction with Raf [15]. RASSF1A inhibits these 
phosphorylation events by blocking the activating phosphorylation of AKT on S473 
[13]. The direct mechanism of AKT inhibition by RASSF1A has not been reported. 
S473 phosphorylation of AKT is regulated by the mammalian target of rapamycin 
complex 2 (mTORC2) [13, 226], which in turn is activated by Ras [227]. Thus, 
control of AKT by RASSF1A may not be direct, but instead mediated through 
control of RAS activation. 
Because of its apoptotic nature and frequent inactivation in premalignant 
tissue, it was long suspected that RASSF1A suppression was an important step in 
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Ras-mediated tumorigenesis. In 2018, the definitive experiment proving this 
hypothesis was performed [14].Using rassf1 transgenic mice that also harbored a 
doxycycline-inducible krasG12V mutation specifically in type II pneumocytes, it was 
shown that loss of one allele of rassf1 was sufficient to significantly enhance Ras-
mediated tumor initiation and growth. These tumors exhibited simultaneous 
activation of the three canonical Ras effector pathways. Moreover, loss of one 
allele of rassf1a alone—without induction of mutant kras—was sufficient to 
enhance Ras mitogenic signaling in normal lung tissue [14]. This suggested that 
perhaps RASSF1A loss can stimulate RAS. In the course of studying the tumor 
suppressive activities of RASSF1A, this lab commissioned a yeast two-hybrid 
screen, using RASSF1A as bait, to identify novel binding partners (Myriad 
Genetics, Salt Lake City, UT). The RasGAP DAB2IP was identified as a binding 
partner for the 37-120 aa region of RASSF1A, which contains the cysteine-rich 




We hypothesized that RASSF1A may regulate Ras by enhancing the Ras-
RasGAP interaction. Thus, we began our investigation by confirming the 
interaction between RASSF1A and DAB2IP. 
 
3.2.1. DAB2IP co-localizes with RASSF1A at the microtubules  
 
 
 62  
RASSF1A is an important regulator of microtubule dynamics, and as such 
prominently localizes to the microtubules when overexpressed [151, 152, 228]. 
The subcellular localization of DAB2IP is more complex. DAB2IP plays an 
important role in regulating neuron and dendrite growth in the developing brain 
[229-231]. Thus, its localization in these specialized cells is well characterized. Its 
localization in other tissues has not been well characterized. DAB2IP has been 
detected at the plasma membrane, in a complex with TNFR in resting cells [182]. 
As DAB2IP is a RasGAP, it is undoubtedly recruited to the plasma membrane in 
response to Ras activation. We determined whether RASSF1A and DAB2IP co-
localized in mammalian cells using transient transfection of fluorescent-tagged 
expression constructs in COS-7 cells (figure 8). GFP and Katushka (KATE) 
expression constructs were used as negative controls. Katushka is a far-red 
fluorescent protein derived from E. quadricolor [232, 233]. As expected, the 
negative controls nonspecifically filled the cytoplasm, whereas RASSF1A was 
localized to microtubules. When expressed alone, DA2BIP filled the cytoplasm; 
however, co-expression of RASSF1A and DAB2IP results in recruitment of 
DAB2IP to the microtubules with RASSF1A. 
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Figure 8. RASSF1A and DAB2IP colocalize in COS-7 cells. COS-7 cells were 
transiently transfected for 24 hours with GFP-tagged DAB2IP and KATE-tagged 
DAB2IP either together or with the empty expression vector of the other protein. 
RASSF1A prominently localizes at the microtubules when overexpressed alone, 
whereas DAB2IP fills the cytoplasm. When together, RASSF1a recruits DAB2IP 
to the microtubules. Representative images were captured using an IX50 inverted 
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3.2.2. RASSF1A associates with DAB2IP independent of Ras 
 
 To ensure the co-localization of DAB2IP and RASSF1A observed in COS-
7 cells was due to direct association of the two proteins, we performed transient 
overexpression of epitope-tagged constructs followed by co-immunoprecipitation 
assays (figure 9). We hypothesized that RASSF1A mediated its suppression of 
Ras through scaffolding activated Ras to its RasGAP inhibitor. Thus, we expected 
the RASSF1A-DAB2IP interaction to be dependent on Ras activation and so 
included a constitutively activate K-RasG12V mutant in our study. To our surprise, 
we found that inclusion of the Ras mutant did not enhance the association between 
HA-RASSF1A and GFP-DAB2IP. 
 Finally, we sought to detect the endogenous association of RASSF1A and 
DAB2IP in human cells (figure 10). RASSF1A is a difficult protein to detect 
endogenously. It is a tumor suppressor and inhibitor of cell cycle progression, and 
thus is expressed at low levels in normal tissues. Its expression is commonly 
suppressed in human tumors and cancer cell lines, compounding the issue. 
Antibodies against RASSF1A that are suitable for immunoprecipitation are not 
commercially available. Moreover, α-RASSF1A antibodies for Western blotting are 
not very sensitive in our hands, and detecting endogenous RASSF1A requires 
resolving large amounts of protein on gels. To provide the most favorable 
conditions possible, we performed endogenous co-immunopreciptation in MCF-
10A breast epithelial cells. This is a non-transformed epithelial cell line. While not 
a lung cancer cell line, we chose to use MCF-10A cells for this assay  
 








Figure 9: RASSF1A and DAB2IP co-immunoprecipitate when overexpressed. 
HEK-293T cells were co-transfected with GFP-DAB2IP, HA-RASSF1A and 
oncogenic K-RasG12V for 24 hours. Cells were lysed and lysates were 
immunoprecipitated (IP) with GFP-nAb™ agarose beads and immunoblotted (IB) 


































Figure 10: RASSF1A and DAB2IP form an endogenous complex. Whole cell 
lysates were prepared from MCF-10A cells. Lysates were immunoprecipitated (IP) 
with a rabbit polyclonal RASSF1A antibody (Prosci, Poway, CA) and anti-rabbit 
IgG immunoprecipitation beads for 16 hours and immunoblotted (IB) for DAB2IP. 
Whole cell lysates served as a positive control. Anti-RASSF1A/IgG beads 
incubated in lysis buffer and IgG beads incubated in whole cell lysate were used 
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because they can be easily grown in large quantities and express relatively high 
amounts of RASSF1A compared to cancer cell lines. Using a rabbit polyclonal 
antibody against RASSF1A (generated by Prosci using the peptide 
ELRELAPAGRAGKGRTRLER, [14]) we successfully detected the endogenous 
interaction between DAB2IP and RASSF1A.  
 
3.2.4. RASSF1A regulates DAB2IP protein levels 
 
 To identify a biological role for the novel RASSF1A-DAB2IP tumor 
suppressor complex, we chose to disrupt the interaction using shRNA-mediated 
knockdown of each protein alone and in combination. The use of shRNAs is not 
as clean or cutting-edge as newer techniques such as CRISPR-Cas9-mediated 
knockout. However, we chose this method of gene suppression because it more 
accurately mimics the method of RASSF1A and DAB2IP suppression in lung 
tumors of real patients. The expression and activities of RASSF1A and DAB2IP 
are both suppressed frequently in lung cancer; however, neither is usually lost 
entirely. Mutations in these genes are rare, therefore functional ablation of their 
signaling activities is not a physiological mechanism of suppression in this case. 
The major mechanism of RASSF1A and DAB2IP suppression in cancer is 
promoter hypermethylation [171, 234]. Thus, expression is reduced, sometimes 
substantially, but rarely completely absent. Indeed, the suppressed-but-not-absent 
state of Ras effectors in cancer may be of particular importance in Ras-driven 
tumors, as mutant Ras may be supported by the remaining wild-type alleles [137].  
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 In the mouse study, effects of RASSF1A on Ras mitogenic signaling were 
observed in mutant K-Ras -induced and -uninduced tissues [14]. Thus, for these 
experiments we chose to employ the use of NCI-1437 NSCLC cells, which retain 
wild-type Ras expression, and NCI-H1792 NSCLC cells, which harbor a 
heterozygous mutation in KRAS, resulting in a G12C substitution [207, 235, 236]. 
When we confirmed the knockdown of RASSF1A and DAB2IP in these cells, we 
found that expression of the shRNA-mediated knockdown of RASSF1A caused a 
striking reduction in DAB2IP protein levels (figure 11). This was not a nonspecific 
effect of the shRNA as NCI-H1792 and NCI-H1473 were transfected with different 
shRNA constructs and selected using different resistance markers. Moreover, 
stable re-expression of RASSF1A in NCI-H1299 cells, which lack endogenous 
RASSF1A expression, increased DAB2IP protein levels (figure 12). 
 RASSF1A has been shown to regulate the stability of other cellular proteins, 
in part through regulating proteasomal degradation [144, 148, 237, 238]. DAB2IP 
has been shown to contain phosphodegron sequences that target it for 
degradation by FBW7-SCF complexes [171]. We hypothesized that RASSF1A 
may regulate DAB2IP stability by inhibiting its proteasomal degradation. To test 
this, we treated NCI-H1792 cells with the proteasome inhibitor MG-132. MG-132 
treatment had no significant effect on DAB2IP protein levels in these cells (Figure 
13a). We also inhibited lysosomal activity by treating 
  
 







Figure 11: Confirmation of shRNA knockdown of RASSF1A/DAB2IP in NCI-
H1792 and NCI-H1437 cells. NCI-H1792 cells expressing pSM1-shRASSF1A or 
empty vector [11], were transfected for 24 hours with pGIPZ-shDAB2IP or empty 
vector. pGIPZ contains a GFP marker, and GFP-positive cells were isolated using 
a MoFlo XDP cell sorter (Beckman Coulter), and then selected in 2.5 μg/mL 
puromycin. NCI-1437 cells were sequentially transfected and selected with pGIPZ-
shDAB2IP/pBRS-shRASSf1A and 1.5 μg/mL puromycin/6 μg/mL blasticidin, 
respectively. Cells were maintained as an early-passage pooled population and 
knockdown was confirmed via Western blot. Band density was quantified using 
ImageJ and DAB2IP fold change was calculated by normalizing to vector-
expressing cells.  
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Figure 12: Exogenous re-expression of RASSF1A upregulates DAB2IP in 
lung cancer cells. NCI-H1299 cells stably expressing pZip-HA-RASSF1A or 
empty vector [11] were transfected for 24 hours with pGIPZ-shDAB2IP or empty 
vector and selected in 1 μg/mL puromycin. Cells were maintained as an early-
passage pooled population of cells, and DAB2IP knockdown was confirmed via 
Western blot. Band density was quantified in ImageJ and DAB2IP fold change was 
































Figure 13. Effects of chloroquine and MG-132 treatment on DAB2IP protein 
levels in NCI-H1792 cells. NCI-H1792 cells were treated with either 50 μM 
chloroquine for 24 hours or 50 μM MG-132 for 4 hours. Cells were lysed in RIPA 
buffer and DAB2IP levels were measured via Western blot. Experiments were 
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the cells with chloroquine [239]; however, lysosomal inhibition also had no effect 




 The RASSF1A tumor suppressor is an important mediator of Ras-induced 
apoptosis [11, 122, 138, 238, 240]. RASSF1A expression is frequently suppressed 
in human tumors by promoter hypermethylation [223, 241-245]. Loss of RASSF1A 
activity uncouples oncogenic Ras from pro-apoptotic signaling and facilitates 
unrestrained Ras mitogenic activity. Furthermore, reports of RASSF1A modulating 
Ras mitogenic activity suggest that RASSF1A may also directly regulate Ras 
activation [13, 14, 16, 17]. 
In our studies, we identified a novel binding interaction between RASSF1A 
and another tumor suppressor, DAB2IP, that is an important GAP for RAS [18, 37, 
180]. Thus, we hypothesized and confirmed that RASSF1A and DAB2IP form an 
endogenous complex in human cells. However, while we expected this interaction 
to be regulated by Ras activation, we found that RASSF1A associated with 
DAB2IP irrespective of Ras activation. Perhaps our most important observation 
was that shRNA-mediated knockdown of RASSF1A significantly downregulated 
DAB2IP protein levels. 
These results clearly demonstrate a physiological interaction between 
RASSF1A and DAB2IP, but the exact function of the interaction remains elusive. 
The function of RASSF1A as a scaffolding protein for Ras guided our initial 
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investigation in to the RASSF1A-DAB2IP complex. Ras activation has been shown 
previously as a prerequisite for interactions between RASSF proteins and their 
effectors [11, 137, 246, 247]. However, in our co-immunoprecipitation studies we 
observed no such dependence on Ras activity of the interaction between DAB2IP 
and RASSF1A. What we did find was that RASSF1A upregulates DAB2IP proteins 
levels in human NSCLC cells. 
Ras is rendered constitutively active by point mutation in many tumors [35]. 
However, this is not the only mechanism by which Ras can be rendered 
hyperactive. Aberrant activity of Ras-regulating proteins, GEFs and GAPs, can 
also give rise to Ras-driven tumors. Such is the case in the RASopathy Noonan 
syndrome, a familial cancer syndrome frequently caused by germline activating 
mutations in the Ras/MAPK pathway [248]. While germline mutations in Ras genes 
themselves are to blame for some cases, in others, mutations in upstream 
activators of Ras such as SOS1 have been reported [249, 250]. Another 
RASopathy, neurofibromatosis type 1 (NF1), is caused by deleterious mutation in 
the RasGAP gene NF1 [251]. In addition, deletions in NF1 may occur in up to 25% 
of breast tumors [252]. Multiple RasGAPs, including DAB2iP have been found to 
be dysregulated in human cancer [169]. This dysregulation can be critical tumor 
progression. Indeed, suppression of DAB2IP is a frequent event and primary driver 
in prostate cancer [167, 200]. Thus, the loss of DAB2IP upon RASSF1A 
suppression is likely a significant contributor to the phenotype observed in 
RASSF1A-deficient cells. 
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DAB2IP is regulated at the levels of transcription, translation, and post-
translation. Phosphorylation is the predominant post-translational modification of 
DAB2IP, resulting in its activation, inhibition, or targeting for proteasomal 
degradation depending on the phosphorylated residue [178, 184]. Interestingly, 
DAB2IP is inhibited by AKT via phosphorylation at S847, which targets DAB2IP for 
proteasomal degradation [178]. RASSF1A inhibits AKT [13]. Thus, RASSF1A may 
stabilize DAB2IP by inhibiting its AKT-mediated degradation. However, this 
mechanism involves the proteasome, and proteasomal inhibition with MG-132 did 
not significantly affect DAB2IP protein levels (figure 4). Antibodies to detect 
phosphorylated residues of DAB2IP are not commercially available, therefore the 
effect of RASSF1A on DAB2IP phosphorylation cannot be determined by Western 
blot. DAB2IP was not previously identified as being under the transcriptional 
control of RASSF1A [253]. However, comparison of RASSF1A and DAB2Ip 
expression in lung adenocarcinoma tumors in The Cancer Genome Atlas (TCGA), 
reveals a strong correlation (figure 14), suggesting that the control of DAB2IP by 
RASSF1A may be transcriptional in nature after all. Additionally, DAB2IP 
expression is also regulated by microRNAs [177, 194, 254, 255]. Thus, it is 










Figure 14: Correlation of RASSF1A and DAB2IP expression in patient lung 
adenocarcinoma tumors. RNA-seq expression analyses of RASSF1 and 
DAB2IP genes in human lung adenocarcinoma tumor and normal tissue samples 
in The Cancer Genome Atlas (TCGA) were accessed through GEPIA [256]. Log 2 
of transcripts per kilobase million (TMP) of DAB2IP was plotted against that of 






















































































































































































































































































































































































































































































































































 While deregulated Ras is a potent oncoprotein, properly regulated Ras 
signaling plays an important, and sometimes indispensable role in embryogenesis 
and tissue homeostasis [257-259]. Normal activation of Ras involves a multi-
protein complex consisting of Ras, receptor tyrosine kinases, adaptor molecules, 
and GEFs [24]. A classical example is EGFR-GRB2-SOS1-Ras. All of these 
proteins can be overexpressed or mutationally activated in cancer, leading to 
enhanced Ras-MAPK signaling [260-262]. Less is known about how the 
inactivation of Ras is regulated. However, the Ras-RasGAP interaction is direct, 
and the most common mutations in Ras render it constitutively active by preventing 
the catalytic subunit of RasGAPs from being properly positioned in the Ras active 
site [38]. Mutation of the RasGAP NF1 is both the basis of a familial cancer 
syndrome and detectable in sporadic human tumors [33, 34, 263]. Other 
RasGAPs, such as DAB2IP, are not commonly mutated in cancer. Rather, their 
expression is suppressed by epigenetic mechanisms [169, 171]. These alternative 
mechanisms of Ras dysregulation play important roles in disease. For example, 
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Ras mutations occur in less than 5% of breast tumors [35]. However, elevated 
Ras-MAPK signaling is detected in approximately 50% of breast tumors, 
particularly in aggressive subtypes, due to dysregulation upstream and 
downstream of Ras [170, 197, 264-266]. 
 DAB2IP is downregulated in breast, lung, prostate, and gastrointestinal 
cancer [171]. The GTPase activity of DAB2IP was identified when it was first 
discovered [18]. GAP activity against Ras is an important mechanism of DAB2IP-
mediated tumor suppression, but it is only partially responsible for the full tumor 
suppressive phenotype of DAB2IP [37]. DAB2IP is a multi-faceted tumor 
suppressor, that also acts independently of Ras to regulate multiple cellular 
processes critical to cancer progression, including EMT, proliferation, and 
apoptosis/survival [36]. 
 DAB2IP utilizes independent domains to simultaneously suppress tumor 
initiation and metastasis [167]. Through the GAP domain, DAB2IP suppresses 
Ras-MAPK signaling and inhibits tumor initiation/growth. DAB2IP also inhibits 
metastasis by inhibiting NFκB activation. Ras stimulates NFκB [267, 268]. 
Therefore, DAB2IP-mediated inhibition of Ras may indirectly suppress NFκB to 
some extent; however, GAP activity is dispensable for DAB2IP-mediated 
suppression of NFκB [167]. Indeed, suppression of NFκB is part of the pro-
apoptotic transduction of TNFR signaling by DAB2IP, wherein phosphorylated 
DAB2IP simultaneously inhibits pro-survival signaling through NFκB and activates 
the pro-apoptotic ASK/JNK pathway [180, 182, 184, 189]. Interestingly, Raf inhibits 
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ASK1 activation [269, 270]. Thus again, GAP activity may play an indirect role in 
potentiating a GAP-independent process of DAB2IP.  
 A third convergence of GAP-dependent and -independent activities of 
DAB2IP involves the PI3K-AKT pathway. As a canonical Ras effector, GAP activity 
obviously suppresses PI3K activation. However, it has been shown that DAB2IP 
can directly bind the p85 regulatory subunit of PI3K, sequestering the p85-p110 
complex and preventing its activation of AKT [165]. This also requires TNF-
dependent phosphorylation of DAB2IP, and is therefore part of its anti-survival/pro-
apoptotic activity. 
 DAB2IP is a complex tumor suppressor that is tightly interwoven with Ras 
signaling. DAB2IP restrains Ras-mediated tumorigenesis by inhibiting Ras itself 
and its effectors, canonical or otherwise, by distinct Ras-dependent and -
independent mechanisms. Thus, loss of DAB2IP expression in cancer 
substantially disrupts homeostatic signaling and favors tumor growth and 
metastasis [37, 169, 171]. We have found that DAB2IP protein levels are regulated 
by RASSF1A and that suppression of RASSF1A, an exceedingly common event 
in cancer [127, 131], markedly downregulates DAB2IP (see section 3.2). We 
suspected that this phenomenon may underlie the effects on Ras signaling 
observed upon suppression of RASSF1A, and thus analyzed the growth and 
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 We hypothesized that RASSF1A knockdown cells would exhibit enhanced 
growth and activation of Ras mitogenic pathways due to elevated basal levels of 
Ras-GTP. As epigenetic suppression of DAB2IP is itself a frequent occurrence in 
lung cancer, we further hypothesized that co-suppression of RASSF1A and 
DAB2IP would synergistically enhance Ras activation. 
 
4.2.1. RASSF1A and DAB2IP cooperatively regulate Ras activation 
  
 GAP activity is critical to DAB2IP-mediated suppression of tumor initiation 
and growth [167]. We have previously shown in a mouse model of K-Ras-driven 
lung cancer that loss of one allele of rassf1a stimulated signaling through canonical 
Ras mitogenic effectors Raf, PI3K, and RalGDS in mutant- and wild-type-Ras 
tissues, suggesting that RASSF1A may directly regulate Ras [14]. We wanted to 
determine if the loss of DAB2IP observed upon shRNA knockdown of RASSF1A 
resulted in a corresponding increase in GTP loading onto Ras. For this, we 
performed active Ras pulldown assays and compared the amount of Ras-GTP 
precipitated to the total amount of Ras in standardized aliquots of whole cell lysate 
(figure 15). Consistent with our hypothesis and previous results, elevated levels of 
Ras-GTP were detected in RASSF1A knockdown cells for both NCI-H1792 and 
NCI-H1437 cell lines. Moreover, in both cells, co-suppression of RASSF1A and 
DAB2IP potentiated this effect. 
 We chose to assess the activation state of a canonical Ras mitogenic 
pathway to confirm our results from the active Ras pulldown assay. Thus, we 
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analyzed both cell lines for PI3K activity during log phase growth via Western blot, 
using P-S473 AKT as a readout (figure 16). We found in both cell lines that P-S473 
AKT was undetectable in control and DAB2IP-knockdown cells. RASSF1A 
knockdown elevated AKT activation, and addition of the DAB2IP shRNA to 
RASSF1A knockdown cells potentiated this effect. 
 
4.2.2. Effects of RASSF1A and DAB2IP on NSCLC growth 
 
 In the mouse model, heterozygosity at the rassf1a locus significantly 
increased lung tumor burden upon induction of the K-Ras mutant compared to 
wild-type littermates. Moreover, loss of one allele of rassf1a in normal, wild-type 
Ras tissue significantly increased Ras mitogenic signaling [14]. We wanted to 
determine if such a role could be established for RASSF1A in our knockdown cells. 
To that end, we measured in vitro growth in our mutant K-Ras cells (figure 17a). 
Knockdown of DAB2IP alone modestly but insignificantly enhanced 2D growth, 
whereas RASSF1A significantly enhanced growth. Co-suppression of 
DAB2IP/RASSF1A had little effect above that of RASSF1A knockdown alone.  
 We also assessed in vitro 2D growth in our wild-type Ras NCI-H1437 
matched set (figure 17b). Interestingly, here we observed synergy between 
RASSF1A and DAB2IP. Only co-suppression of both proteins significantly 
increased 2D growth. This synergistic effect fit well with the Ras and AKT activation 
observed in these cells. So, we chose to further examine this cell line to determine 
if RASSF1A and DAB2IP would synergize in vivo. We injected our NCI-H1437 
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matched set subcutaneously into NRG mice, and measured the volume of the 
resultant xenograft tumors over the course of several weeks (figure 18). 
Knockdown of DAB2IP alone had no effect on tumor growth, whereas RASSF1A 
knockdown modestly increased tumor growth. Similar to in vitro growth, co-
suppression of RASSF1A and DAB2IP significantly enhanced in vivo growth of 
NCI-H1437 cells. 
 Finally, we examined Ras pathway activation in tumor lysates via Western 
blot (figure 19). In the dual knockdown tumors, we observed consistent, statistically 
significant upregulation of MAPK pathway activation compared to control tumors. 
Dual knockdown also resulted in the highest PI3K-AKT pathway, although this 




 RASSF1A plays an indispensable role in homeostasis in large part by 
restraining Ras-mediated transformation [129]. Canonical RASSF1A signaling is 
primarily centered on induction of apoptosis in response to Ras activation [9, 127]. 
Indeed, the growth-inhibitory response to mutant Ras activity constitutes a 
molecular hurdle that must be overcome in order for transformation to occur [271]. 
Hints of a more pleiotropic role for RASSF1A in modulating Ras activity have been 
published throughout the years [13, 14, 16, 17]. Here, we provide further evidence 
for a novel, regulatory role for RASSF1A in Ras signaling.  
 










Figure 15. Effects of RASSF1A/DAB2IP suppression on Ras activation. Cells 
were seeded at low density in 10 cm dishes and growth for 72 hours, after which 
whole cell lysates were prepared. Ras-GTP was precipitated for 1 hour using the 
Ras binding domain (RBD) of Raf-1 conjugated to agarose. Precipitated Ras-GTP 





































Figure 16: Effects if RASSF1A/DAB2IP suppression on in vitro Ras signaling. 
Cells were seeded at low density and growth for 48 hours, after which whole cell 
lysates were prepared. AKT activation was determined via Western blot analysis 





































Figure 17. In vitro growth curves of NCI-H1792 and NCI-H1437 matched sets 
of cells. Cells were plated at 104 cells per well in 9 wells of 6-well plates. Triplicate 
wells were counted 24 hours after plating as day 0, then again on days 3 and 7. 
Cell numbers are reported as mean ± s.e. **** p < 0.0001 
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Figure 18: NCI-H1437 xenograft growth curve. Cells were seeded at low density 
in several large flasks and incubated for 48 hours to achieve log-phase growth. 106 
cells in 1X PBS were injected subcutaneously into the left flank of NRG mice. 
Resultant tumors were measured using calipers. Tumor volume was calculated by 
the formula 𝑉 = #	×	%
&
'
 . Volumes are reported as mean ± s.e. n = 5 or 6. p ≤ *0.05, 
**0.01, ****0.0001. 
  

































Figure 19: Effects of RASSF1A/DAB2IP suppression on in vivo Ras 
signaling. NCI-H1437 xenograft tumors were harvested from sacrificed animals 
and lysates were prepared. Equal protein masses of each tumor lysate were 
analyzed for MAPK and PI3K-AKT activity via ERK 1/2 T-202/Y-205 and AKT S-
473 phosphorylation, respectively. Bands were quantified using ImageJ and 
activation fold change was calculated by normalization to control cells. n= 5 or 6. 
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Having demonstrated the ability of RASSF1A to upregulate DAB2IP, an 
important RasGAP, we speculated that this modulation of DAB2IP protein levels 
would be transduced through Ras mitogenic activity and affect the growth of our 
matched sets of NSCLC cells. We anticipated that the effects on Ras signaling and 
cell growth would apparent in both cell lines, despite the NCI-H1792 cells harboring 
an oncogenic K-Ras mutant, for several reasons. First, the specific mutation found 
in NCI-H1792 cells, G12C, actively—and rapidly—cycles between GTP- and GDP-
bound states, suggesting that it retains some sensitivity to GAP action [115, 272]. 
Second, we have reported that loss of RASSF1A potentiates mitogenic signaling 
mediated by mutant K-Ras in vivo [14]. Finally, the remaining wild-type Ras alleles 
are certainly still susceptible to GAP activity, and their activation may support the 
oncogenic action of the mutant allele [137]. 
In both wild-type and mutant Ras cell lines, we observed striking 
upregulation of Ras-GTP and downstream activation of AKT upon co-suppression 
RASSF1A and DAB2IP. Analysis of growth in these cells, however, gave disparate 
results. In the mutant Ras cells, suppression of RASSF1A alone significantly 
enhanced 2D growth compared control cells in agreement with the Ras activity 
detected in these cells. Dual inactivation of RASSF1A/DAB2IP had an insignificant 
effect over that of RASSF1A suppression alone, despite these cells exhibiting the 
strongest Ras activation in the pulldown and signaling assays. One possible 
explanation for this is that concomitant suppression of RASSF1A and mutation of 
Ras maximally stimulates growth, such that further stimulation of Ras from 
suppression of DAB2IP confers no additional benefit. The interplay between 
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RASSF1A and DAB2IP has not been studied previously in any capacity. However, 
this explanation is in agreement with clinical observations in lung cancer patients, 
in that those tumors with dual mutation in KRAS and hypermethylation of the 
RASSF1A promoter are highly aggressive and confer a poor prognosis [273]. 
In wild-type Ras cells, we observed a synergistic effect between RASSF1A 
and DAB2IP suppression on 2D growth. Excited by this result, we chose to further 
examine the biology of these cells in vivo. Here, we found that suppression of 
RASSF1A alone significantly increased Ras activation and growth in NCI-H1437 
xenografts, and this effect was compounded by addition of the DAB2IP shRNA. 
The discrepancy between the in vitro and in vivo results remains unresolved; 
however, the effect of RASSF1A on DAB2IP protein levels may be responsible. 
DAB2IP is known to inhibit angiogenesis through inhibition of VEGFR-2 [164]. 
Angiogenesis is critical to tumor growth, as oxygen and nutrient availability at the 
center of the tumor become limited by diffusion in avascular tissue once the tumor 
is just a few cubic millimeters in size [274, 275]. Hypoxia at the core of a tumor 
induces the expression of hypoxia-inducible factors (HIFs), transcription factors 
that regulate genes that aid cells in handling hypoxic stress [276]. Loss of DAB2IP 
has been shown to upregulate HIF-1α and HIF-2α [193, 277, 278]. Thus, 
suppression of DAB2IP confers a growth and survival advantage in vivo that is not 
otherwise apparent experimentally. Since knockdown of RASSF1A caused a 
greater reduction in DAB2IP protein levels than the DAB2IP shRNA, disinhibition 









 The work presented in this dissertation identifies a novel role for RASSF1A 
in the regulation of the RasGAP DAB2IP. It tracks the transduction of this 
regulatory event from its start in regulating Ras activation, through the modulation 
of Ras mitogenic signaling, down to its terminal phenotypic output of suppressing 
tumor growth. In so doing, it furthers our mechanistic understand of RASSF-
mediated tumor suppression and begins to answer the lingering question of why 
loss of RASSF1A enhances the mitogenic activity of Ras. 
 We found that RASSF1A forms an endogenous complex with the RasGAP 
DAB2IP. Unexpectedly, this interaction was not regulated by Ras. Preliminarily, 
our data suggest that RASSF1A stabilizes DAB2IP protein; however, this was not 
mediated through inhibition of proteasomal or lysosomal degradation of DAB2IP. 
  RASSF1A has previously been shown by our group and others modulate 
the activation of Ras mitogenic pathways [13, 14, 17]. However, the mechanisms 
underlying these phenomena are not completely clear. Here, we demonstrate a 
clear upregulation of Ras-GTP in response to RASSF1A suppression. Thus, the 
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effects of RASSF1A on Ras signaling are not caused by the complex interactions 
between RASSF1A and mitogenic Ras effectors, or at least not fully, but involves 
direct control of Ras activation. To our knowledge, this is the first example of a 
downstream effector of Ras modulating an upstream regulator of Ras. 
 Of note, the effect of RASSF1A on Ras activation is not limited to only wild-
type Ras tumors, but can be observed in mutant Ras cancer cells as well. The 
implications of this novel regulatory event may not be immediately apparent. Gene 
therapy is not yet the standard of care in cancer treatment, and therefore knowing 
that one of the most frequently inactivated tumor suppressors can regulate the 
most frequently activated oncoprotein does not immediately reveal a useful 
therapeutic target. However, the renewed quest to effectively drug Ras as cancer 
treatment suggests that this regulatory event may be of therapeutic import after all. 
 Novel inhibitors of K-RasG12C function by trapping mutant Ras in the inactive 
state, demonstrating that the mutant is not completely devoid of GTPase activity 
and may still be stimulated by RasGAPs. In fact, the notion that Ras mutants are 
locked in an active state has recently been brought into question, as other common 
Ras mutants (G13D and Q61L specifically) have also been shown to retain intrinsic 
GTPase activity that is, though diminished, still comparable to wild-type Ras [279]. 
Therefore, RASSF1A-mediated loss of GAP expression may dampen the 
hydrolytic potential of Ras mutants, thereby reducing the pool of Ras-GDP 
available for inhibitors to bind. These novel inhibitors may rely on the intact 
regulatory machinery of Ras. In the same vein, though in diametrical opposition to 
the former in approach, a 2019 report showed that growth of lung cancer cells 
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could be inhibited by treatment with a small molecule agonist of K-RAS [280]. 
Pharmacological activation of K-Ras restricted cell growth by inducing apoptosis 
and autophagy. Loss of RASSF1A/DAB2IP dually uncouples Ras from its 
apoptotic effectors and substantially elevates the basal activation state of Ras. 
Hypothetically, then, RASSF1A/DAB2IP loss may elevate Ras activation and 
suppress Ras-mediated apoptosis to such a degree that further activation by the 
small molecule is incapable of eliciting an apoptotic response. As drug discovery 
in the Ras field continues, the importance of these little-known (and perhaps still 
unknown) regulatory mechanisms controlling Ras may become more apparent. 
 
5.2. Future Directions 
 
 The original goal of this work was to confirm and characterize a novel 
binding interaction between RASSF1A and DAB2IP. While generating the 
reagents necessary to investigate the biological significance of the RASSF1A-
DAB2IP interaction, we made another novel—and unexpected—discovery: 
RASSF1A upregulates DAB2IP. Thus, we turned our attention to investigating the 
effects of this novel regulatory event on growth and signaling in cancer. 
 In the course of our studies, we did elucidate a novel mechanism of 
RASSF1A-mediated regulation of Ras activation. However, several questions 
remain as to the function of the RASSF1A-DAB2IP complex. First, mapping the 
site of interaction on both DAB2IP and RASSF1A would allow for the generation 
of binding-defective mutants. These mutants would be critical to elucidating what 
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biological effects are directly attributable to the RASSF1A-DAB2IP interaction 
itself. RASSF1A and DAB2IP have several overlapping activities, including 
inhibition of AKT, induction of apoptosis, and regulation of inflammation. Therefore, 
it is important to distinguish which effects are due to the binding event versus the 
additive output of two independent mechanisms. 
 Additionally, the ability of other RASSF proteins to bind and/or regulate 
GAPs may be a worthwhile investigation. RASSF proteins are capable of 
dimerizing with each other, and therefore may cooperatively mediate tumor 
suppression [281]. Moreover, RASSF proteins exhibit some redundancy in effector 
binding and signaling activity [9, 37]. Indeed, we have seen that other RASSF 
family members can bind DAB2IP in overexpression systems (unpublished 
observation). Thus, regulation of small GTPases may be a common attribute of 
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